<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Contraception: Issues specific to adolescents
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Contraception: Issues specific to adolescents
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Contraception: Issues specific to adolescents
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Mariam R Chacko, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Amy B Middleman, MD, MPH, MS Ed
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Diane Blake, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Aug 04, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         This topic review will provide an overview of issues related to the provision of contraceptive services to adolescent females. Emergency contraception, choosing a contraceptive method, and individual methods of contraception are discussed separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5475.html" rel="external">
          "Emergency contraception"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5459.html" rel="external">
          "Contraception: Counseling and selection"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5419.html" rel="external">
          "Intrauterine contraception: Candidates and device selection"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3266.html" rel="external">
          "Contraception: Etonogestrel implant"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5468.html" rel="external">
          "Depot medroxyprogesterone acetate (DMPA): Formulations, patient selection and drug administration"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7398.html" rel="external">
          "Combined estrogen-progestin oral contraceptives: Patient selection, counseling, and use"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/16682.html" rel="external">
          "Contraception: Hormonal contraceptive vaginal rings"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5425.html" rel="external">
          "Contraception: Transdermal contraceptive patches"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5461.html" rel="external">
          "Contraception: Progestin-only pills (POPs)"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3265.html" rel="external">
          "Pericoital (on demand) contraception: Diaphragm, cervical cap, spermicides, and sponge"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5463.html" rel="external">
          "External (formerly male) condoms"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5471.html" rel="external">
          "Internal (formerly female) condoms"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2514480056">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         In the United States, approximately 80 percent of pregnancies among adolescents age 15 to 19 years are unintended [
         <a href="#rid1">
          1
         </a>
         ]. In national surveys, approximately one-fourth of high school students report that they are sexually active (defined by having sexual intercourse in the previous three months) [
         <a href="#rid2">
          2
         </a>
         ]. Among sexually active students, only one-third used an effective method of contraception (ie, long-term reversible contraception or short-term hormonal contraception) and one-tenth did not use any method. The risk of pregnancy over the course of one year in couples who do not use any method of contraception is approximately 85 percent [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
         Among female high school students responding to the 2021 Youth Risk Behavior Surveys [
         <a href="#rid2">
          2-4
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         22 percent were currently sexually active and during their last sexual intercourse:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         47 percent used a condom
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         23 percent used birth control pills
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         5 percent used a shot, patch, or birth control ring
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         10 percent used an intrauterine device (IUD) or contraceptive implant
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         10 percent used a condom plus a highly effective/effective contraceptive method
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         15 percent did not use any method to prevent pregnancy
        </p>
        <p>
        </p>
        <p>
         Similarly, data from the 2011 to 2015 National Survey of Family Growth indicate that, among females age 15 to 19, condoms remained the most common method ever used (97 percent), followed by withdrawal (60 percent), oral contraceptive pills (56 percent), and depot
         <a class="drug drug_general" data-topicid="9600" href="/z/d/drug information/9600.html" rel="external">
          medroxyprogesterone acetate
         </a>
         (17 percent) [
         <a href="#rid5">
          5
         </a>
         ]. Approximately 6 percent reported ever using long-acting reversible contraception (3 percent each for IUD and contraceptive implant). Compared with the previous survey (2006 to 2010), use of the contraceptive patch decreased (from 10 to 2 percent) and emergency contraception increased (from 14 to 23 percent). Among sexually experienced females, 16 percent reported using no method of contraception at first sexual intercourse. In an earlier survey (2011 to 2013) adolescents age 15 to 19 years who did not use any method of contraception at their first sexual intercourse were twice as likely to become mothers before age 19 years than those who used contraception at their first sexual intercourse (26 versus 10 percent) [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          MOTIVATING FACTORS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The sexually active adolescent is more likely to seek contraception if they [
         <a href="#rid7">
          7
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Perceive pregnancy as a negative outcome
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Have long-term educational goals
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Are more mature (see
         <a class="local">
          'Developmental factors'
         </a>
         below)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Experience a pregnancy scare or actual pregnancy
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Have family, friends, and/or a clinician who sanction the use of contraception
        </p>
        <p>
        </p>
        <p>
         Sexually active adolescents who do not desire pregnancy but are having difficulty choosing a method may be motivated to make a decision by raising their awareness of their risk of pregnancy (eg, by reviewing the stories of a sister, friend, or peer who is a teen mother) or reviewing their educational goals (eg, graduating from high school, going to college). (See
         <a class="local">
          'Choosing a method'
         </a>
         below and
         <a class="local">
          'Resources for clinicians and patients'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h1">
          POTENTIAL BARRIERS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Barriers to use of contraceptives in adolescents may include [
         <a href="#rid8">
          8-10
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Concerns about confidentiality and parental notification
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cost
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Misperceptions about their risk of getting pregnant and the effectiveness of, contraindications to, preinitiation evaluation for, and adverse effects of contraception
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Knowledge deficits among adolescents and health care providers
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Difficulty accessing contraception
        </p>
        <p>
        </p>
        <p>
         Removal of barriers appears to be associated with increased use of more effective methods of contraception and decreased rates of pregnancy, without increasing coital frequency or the number of male sexual partners [
         <a href="#rid11">
          11-16
         </a>
         ]. In a prospective study, 1404 urban female adolescents (age 15 to 19 years) were educated about reversible contraception, with an emphasis on the benefits of long-acting reversible contraception (LARC); provided with their choice of reversible contraception at no cost; and followed for two to three years [
         <a href="#rid11">
          11
         </a>
         ]. Nearly three-quarters of participants chose an intrauterine device (IUD) or contraceptive implant. Compared with sexually active United States teenagers in 2008, study participants had lower rates of pregnancy (34 versus 158.5 per 1000), birth (19.4 versus 94 per 1000), and abortion (9.7 versus 41.5 per 1000).
        </p>
        <p class="headingAnchor" id="H1548498967">
         <span class="h2">
          Confidentiality and parental consent
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Confidentiality
         </strong>
         – Assuring confidentiality is the first step in establishing basic trust and respect between the clinician and the adolescent patient. The adolescent should be given an opportunity to provide their medical history and to obtain gynecologic and sexual information directly from the clinician. The importance and the limits of confidentiality should be discussed with the adolescent and their parent or guardian at the initial visit. (See
         <a class="medical medical_review" href="/z/d/html/106.html" rel="external">
          "Confidentiality in adolescent health care"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The concept of conditional confidentiality can be introduced to the accompanying parent or guardian as follows:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         "I would like to make this visit a positive experience for your child. It is important to respect an adolescent's privacy as a normal part of growing up. I would first like to have the opportunity to review health information with you, and then I would like to review health information with your child alone. Usually, whatever is discussed between my teenage patients and me is confidential, except in certain situations, such as if they have thoughts of suicide, thoughts of physically harming someone, or reports that they have been or are being physically or sexually abused. If you feel you need to know more about what they and I have discussed, I strongly encourage you and your child to talk to each other directly."
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A young adolescent may prefer to have their parent or caregiver present throughout the office visit, particularly if the caregiver is aware of the teenager's sexual behavior and wants the teenager to use a contraceptive method. Even if this is the case, it is important to encourage independent time with the adolescent to obtain a more detailed history about other possible high-risk behaviors. (See
         <a class="medical medical_review" href="/z/d/html/108.html" rel="external">
          "Guidelines for adolescent preventive services", section on 'Strategy for provision of adolescent preventive services'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The 21
         <sup>
          st
         </sup>
         Century Cures Act was implemented in 2020 to improve medical care by increasing access, use, and exchange of electronic health information. However, the legal right of adolescent minors to receive confidential services in this context has been a challenge. The
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.adolescenthealth.org%2FAdvocacy%2FAdvocacy-Activities%2F2019-%281%29%2FNASPAG-SAHM-Statement.aspx&amp;token=X7hG%2BVrHARmHhW1ICJSZdrRDXw66xe%2BsVURo%2Fo89zCctv5si9chGlVk1AO0YZuiWSvT6Tmhfyc%2FeGCw8I0fx87ZQxc8sgzoy7h0O1%2Bdfup8ghJr2tWTF5uLMTmpNduUjrwC1JCwUsNIWoeWxLU0oqw%3D%3D&amp;TOPIC_ID=107" target="_blank">
          North American Society for Pediatric and Adolescent Gynecology and the Society for Adolescent Health and Medicine
         </a>
         provide additional information about the 21st Century Cures Act and adolescent confidentiality, including recommendations for health care providers [
         <a href="#rid17">
          17
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/106.html" rel="external">
          "Confidentiality in adolescent health care", section on 'Twenty-First Century Cures Act'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Parental consent
         </strong>
         – Clinicians should be familiar with state regulations and local clinic protocols regarding a minor's right to access contraceptive services without parental involvement or notification. The need for parental consent also may be related to state or federal funding for hormonal contraception in local clinics. The Guttmacher Institute maintains a list of state policies regarding
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.guttmacher.org%2Fstate-policy%2Fexplore%2Fminors-access-contraceptive-services&amp;token=1ch2cftP2f4wxQctG4%2BxfapMhAO%2FdG4ZlC9bzN%2FQqaN82P0c45uW474BMhw0axYppmC7%2BRiIWy6GdUjBoskl82vcshe0JmnTZvK5Dib%2Fvp8%3D&amp;TOPIC_ID=107" target="_blank">
          parental involvement
         </a>
         and
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.guttmacher.org%2Fstate-policy%2Fexplore%2Foverview-minors-consent-law&amp;token=WPLlYiGN4sfAHHOr06dbfTWtbCWLEZ54Z8mmPwX9HPfVGKYLFoJfSBcIvEInnHMqXcUOUtMcUuK5B36CKo6kbSQKOX7UiegTv1Z6d%2BNYsPI%3D&amp;TOPIC_ID=107" target="_blank">
          consent
         </a>
         that are updated regularly. (See
         <a class="medical medical_review" href="/z/d/html/105.html" rel="external">
          "Consent in adolescent health care"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2664968120">
         <span class="h2">
          Cost
         </span>
         <span class="headingEndMark">
          —
         </span>
         In the United States, the Patient Protection and Affordable Care Act of 2010 (public law No. 111-148) requires coverage of preventive services for females, including US Food and Drug Administration (FDA)-approved contraceptive methods, without out-of-pocket costs [
         <a href="#rid18">
          18,19
         </a>
         ]. However, adolescents and young adult females who have health insurance through their parents may be reluctant to access such services unless their privacy can be assured [
         <a href="#rid20">
          20
         </a>
         ]. In addition, challenges to this mandate may arise for adolescents in states that opted out of Medicaid Expansion or when adolescents with an insurance plan must seek an in-network provider experienced in offering highly effective contraceptive services [
         <a href="#rid21">
          21
         </a>
         ]. We encourage providers to become familiar with local resources for provision of contraceptives at little or no cost (eg, by asking social workers for a local resource book or trustworthy online program). (See
         <a class="medical medical_review" href="/z/d/html/106.html" rel="external">
          "Confidentiality in adolescent health care", section on 'Potential threats to confidentiality'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1829859373">
         <span class="h2">
          Misperceptions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Adolescent and clinician misperceptions are important barriers to effective adolescent contraception [
         <a href="#rid22">
          22-25
         </a>
         ]. Adolescents may have misperceptions about their risk of getting pregnant (eg, if they have had unprotected sexual intercourse and did not get pregnant, they may believe that they are unable to become pregnant). Adolescents may mistakenly believe that they must have a pelvic examination and cervical inspection before initiation of any method of contraception; this evaluation is necessary only for intrauterine contraception. Both adolescents and clinicians may have misperceptions about the effectiveness of, contraindications to, preinitiation evaluation for, or adverse effects of various methods of contraception [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p>
         It is important to dispel misperceptions of adverse effects, particularly of hormonal methods (eg, the contraceptive implant, oral contraceptive pills, depot
         <a class="drug drug_general" data-topicid="9600" href="/z/d/drug information/9600.html" rel="external">
          medroxyprogesterone acetate
         </a>
         [DMPA]), when discussing contraceptive methods with adolescent patients. Examples of adolescent concerns include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Weight gain
         </strong>
         – Many adolescents are concerned that hormonal contraceptives cause weight gain. However, a causal relationship has not been established. The effects of hormonal contraception on weight are discussed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/118540.html" rel="external">
          "Depot medroxyprogesterone acetate (DMPA): Efficacy, side effects, metabolic impact, and benefits", section on 'Weight changes'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7399.html" rel="external">
          "Combined estrogen-progestin contraception: Side effects and health concerns", section on 'Weight gain'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3266.html" rel="external">
          "Contraception: Etonogestrel implant", section on 'Counseling points'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Effect on height
         </strong>
         – Adolescents may be concerned that hormonal contraception may cause premature closure of the growth plates, reducing their ultimate adult height. However, by the time of menarche, most female adolescents have already undergone their growth spurt and achieved approximately ≥95 percent of their adult height. (See
         <a class="medical medical_review" href="/z/d/html/5849.html" rel="external">
          "Normal puberty", section on 'Growth spurt'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Congenital anomalies and infertility
         </strong>
         – Adolescents may be concerned that hormonal contraception may cause congenital anomalies or infertility. However, evidence to support these associations is lacking. (See
         <a class="medical medical_review" href="/z/d/html/7399.html" rel="external">
          "Combined estrogen-progestin contraception: Side effects and health concerns", section on 'Return of fertility'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Overestimation of the magnitude of risk
         </strong>
         – In some cases, adolescents may be correct that a particular method of contraception is associated with an adverse effect, but may overestimate the magnitude of the risk (eg, decreased bone density with
         <a class="drug drug_general" data-topicid="9600" href="/z/d/drug information/9600.html" rel="external">
          DMPA
         </a>
         , venous thromboembolism [VTE] with hormonal contraception in the absence of underlying risk factors). (See
         <a class="medical medical_review" href="/z/d/html/5425.html" rel="external">
          "Contraception: Transdermal contraceptive patches", section on 'Risk of venous thrombotic events'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7399.html" rel="external">
          "Combined estrogen-progestin contraception: Side effects and health concerns", section on 'Venous thromboembolism'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/118540.html" rel="external">
          "Depot medroxyprogesterone acetate (DMPA): Efficacy, side effects, metabolic impact, and benefits", section on 'Reduction in bone mineral density'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         These side effects must be considered in relation to their risk during pregnancy [
         <a href="#rid27">
          27
         </a>
         ]. As an example, the risk of VTE may be 3- to 10-fold higher in pregnant than in nonpregnant females. (See
         <a class="medical medical_review" href="/z/d/html/1347.html" rel="external">
          "Venous thromboembolism in pregnancy: Prevention"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H524763380">
         <span class="h2">
          Clinician concerns
         </span>
         <span class="headingEndMark">
          —
         </span>
         Clinicians may be concerned about contraindications and/or potential long-term effects (including FDA boxed warnings) of hormonal contraception in adolescents.
        </p>
        <p>
         A comprehensive list of absolute (unacceptable health risks) and relative (theoretic or proven risks usually outweigh the advantages) contraindications to long-acting and hormonal contraceptive methods for females in the United States is available from the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Freproductivehealth%2Fcontraception%2Fpdf%2Fsummary-chart-us-medical-eligibility-criteria_508tagged.pdf&amp;token=p7A56cdQa48oh8HfN4dMPEKlrim7QFIQY%2FuVV%2FJckGU937u1ckJkmkgaK8H2PBoY%2FJ5BEapx7DHdp5gqM%2BK1cZFvupA973jfwqlDuJ3YBVeBCZhIb4QeOsKswDD%2B1dvSISE9r%2BIvb9WDleMu0Qs%2FMQ%3D%3D&amp;TOPIC_ID=107" target="_blank">
          Centers for Disease Control and Prevention
         </a>
         . An easy-to-use pocket-size wheel of the 2015 World Health Organization (WHO) medical eligibility for contraceptive use is available from the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.who.int%2Fpublications%2Fi%2Fitem%2F9789241549257&amp;token=mr3MkQMxxRm373pPGLTYB%2B8L7rJeOJtqYOfpSLq18h7bLDDnWC3XicBcpsIGU3t1KmE%2BlIH4Up7JMM8N%2B0%2B%2BQw%3D%3D&amp;TOPIC_ID=107" target="_blank">
          WHO
         </a>
         [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p>
         Clinician concerns about the potential long-term effects of hormonal contraception (eg, decreased bone density with
         <a class="drug drug_general" data-topicid="9600" href="/z/d/drug information/9600.html" rel="external">
          DMPA
         </a>
         or ultra-low dose combination oral contraceptives) also may be a barrier to provision of contraception to adolescents. These concerns must be weighed against the risk of pregnancy in a young adolescent [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
         Biologic, behavioral/psychological, and environmental factors  (
         <a class="graphic graphic_table graphicRef65312" href="/z/d/graphic/65312.html" rel="external">
          table 1
         </a>
         ) can assist with clinical decision-making when there is concern about the long-term effects of initiating hormonal contraception in young adolescents. As a general rule, the risks of pregnancy in a young teenager with behavioral and environmental risk factors exceed the risks of hormonal contraceptives, particularly when the caregiver is unable to monitor the adolescent.
        </p>
        <p class="headingAnchor" id="H3606365244">
         <span class="h2">
          Difficulty accessing contraception
         </span>
         <span class="headingEndMark">
          —
         </span>
         Many adolescents have difficulty accessing contraceptive services.
        </p>
        <p>
         Evidence-based clinical best practices for adolescents to access contraceptive methods include [
         <a href="#rid29">
          29
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Offering same-day appointments and appointments during after-school hours and on weekends
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Obtaining a sexual health history at every visit
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Offering a wide range of contraceptive methods
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Offering reliable contraception at every office visit to adolescents who are not on reliable contraception
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Prescribing hormonal contraception without prerequisite examinations or testing for sexually transmitted infections
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Offering contraception during an emergency department visit
        </p>
        <p>
        </p>
        <p>
         In one study of 96 adolescents who received brief counseling (average of 12 minutes) during their emergency department visit, 33 percent either initiated a contraceptive method during the visit or at a follow-up referral visit ≤8 weeks later [
         <a href="#rid30">
          30
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H707998035">
         <span class="h1">
          CHOOSING A METHOD
         </span>
         <span class="headingEndMark">
          —
         </span>
         Developmental factors, patient factors (eg, medical history [
         <a href="#rid31">
          31
         </a>
         ], sexual and reproductive history), and patient preferences (eg, convenience, tolerance of side effects) affect the choice of contraceptive method. Contraceptive counseling and selection are discussed in detail separately. Issues that are relatively more important for adolescents are described below. (See
         <a class="medical medical_review" href="/z/d/html/5459.html" rel="external">
          "Contraception: Counseling and selection"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H823388880">
         <span class="h2">
          Developmental factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Adolescent development affects the adolescent's ability to implement and adhere to a contraceptive regimen. From a developmental perspective, sexually active girls in early adolescence (10 through 14 years) have difficulty planning events and activities; they often have an idealistic point of view, think about situations in a concrete or literal way, and live in the moment. Implementing a contraceptive method that requires planning and forethought to prevent the "possibility" of pregnancy is difficult at this stage without monitoring and adult support. Girls in middle adolescence (15 through 18 years) and late adolescence (&gt;18 years) are more capable of higher-level planning, decision making, and problem solving, skills essential to effective contraceptive behavior [
         <a href="#rid32">
          32,33
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/113.html" rel="external">
          "Sexual development and sexuality in children and adolescents", section on 'Adolescent development'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5459.html" rel="external">
          "Contraception: Counseling and selection"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3720305244">
         <span class="h2">
          Patient factors and preferences
         </span>
         <span class="headingEndMark">
          —
         </span>
         A medical, reproductive/sexual, and social history will identify
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Freproductivehealth%2Fcontraception%2Fpdf%2Fsummary-chart-us-medical-eligibility-criteria_508tagged.pdf&amp;token=p7A56cdQa48oh8HfN4dMPEKlrim7QFIQY%2FuVV%2FJckGU937u1ckJkmkgaK8H2PBoY%2FJ5BEapx7DHdp5gqM%2BK1cZFvupA973jfwqlDuJ3YBVeBCZhIb4QeOsKswDD%2B1dvSISE9r%2BIvb9WDleMu0Qs%2FMQ%3D%3D&amp;TOPIC_ID=107" target="_blank">
          absolute (unacceptable health risks) or relative (theoretic or proven risks usually outweigh the advantages) contraindications
         </a>
         and patient factors (eg, anemia, acne, dysmenorrhea) that may affect contraceptive choice  (
         <a class="graphic graphic_table graphicRef89046" href="/z/d/graphic/89046.html" rel="external">
          table 2
         </a>
         ). For most adolescents, the advantages of any method of reversible contraception outweigh the theoretic or proven risks [
         <a href="#rid34">
          34
         </a>
         ].
        </p>
        <p>
         Before discussing contraceptive options and possible contraindications, we evaluate patient preferences regarding childbearing (eg, do they want to prevent pregnancy now?), privacy, convenience, side effects, control or suppression of menstruation, spontaneity, social and cultural factors, etc [
         <a href="#rid35">
          35,36
         </a>
         ]. Patient preferences are discussed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/5459.html" rel="external">
          "Contraception: Counseling and selection", section on 'The shared decision-making process'
         </a>
         .)
        </p>
        <p>
         In surveys or individual patient interviews, factors that are most important to adolescents include effectiveness, duration, convenience/ease of use, and side effects [
         <a href="#rid37">
          37-39
         </a>
         ]. These factors are discussed below.
        </p>
        <p class="headingAnchor" id="H4289369991">
         <span class="h2">
          Abstinence
         </span>
         <span class="headingEndMark">
          —
         </span>
         Complete abstinence from penile-vaginal intercourse is the most effective method of birth control. However, data suggest that adolescents who practice abstinence occasionally have penile-vaginal intercourse [
         <a href="#rid40">
          40
         </a>
         ]. Thus, even adolescents who intend to remain abstinent should receive information about pregnancy prevention (including emergency contraception [EC]) and prevention of sexually transmitted infections [
         <a href="#rid41">
          41
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5475.html" rel="external">
          "Emergency contraception"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7595.html" rel="external">
          "Prevention of sexually transmitted infections"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2709362473">
         <span class="h2">
          Presenting options
         </span>
         <span class="headingEndMark">
          —
         </span>
         When presenting options for contraception to sexually active adolescents, we describe them in order of effectiveness, starting with the most effective options  (
         <a class="graphic graphic_figure graphicRef119765" href="/z/d/graphic/119765.html" rel="external">
          figure 1
         </a>
         ), as recommended by the American Academy of Pediatrics (AAP) [
         <a href="#rid42">
          42
         </a>
         ] and the American College of Obstetricians and Gynecologists (ACOG) [
         <a href="#rid24">
          24
         </a>
         ]. A summary of relevant information is provided in the table  (
         <a class="graphic graphic_table graphicRef89046" href="/z/d/graphic/89046.html" rel="external">
          table 2
         </a>
         ). More detailed information is available in individual topics related to the various methods.
        </p>
        <p class="headingAnchor" id="H707150580">
         <span class="h3">
          Long-acting reversible methods
         </span>
         <span class="headingEndMark">
          —
         </span>
         Intrauterine contraception and contraceptive implants are the two types of long-acting reversible contraception (LARC).
        </p>
        <p>
         LARC methods are the most effective reversible methods of contraception; once they have been inserted they do not require regular action on the part of the adolescent. They are considered first-line options for adolescents by the AAP [
         <a href="#rid42">
          42,43
         </a>
         ] and the ACOG [
         <a href="#rid44">
          44-46
         </a>
         ].
        </p>
        <p>
         In a systematic review of nine studies (26,907 participants) comparing intrauterine device (IUD) with other methods of contraception in females ≤25 years, the 12-month continuation rates were highest for LARC methods (approximately 85 percent compared with 40 to 50 percent for non-LARC methods) [
         <a href="#rid47">
          47
         </a>
         ]. In a prospective cohort study, among 1099 urban adolescents (age 14 to 19 years) who were provided with contraception at no cost, 12-month continuation rates were greater for LARC than for other methods (81 versus 44 percent) [
         <a href="#rid48">
          48
         </a>
         ]. Satisfaction was also greater with LARC than non-LARC methods (75 versus 42 percent).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Intrauterine contraception
         </strong>
         – Intrauterine contraception with the copper or levonorgestrel-releasing (LNG) IUD is an attractive option for adolescents who desire long-term, uninterrupted contraception [
         <a href="#rid49">
          49
         </a>
         ]. Noncontraceptive benefits of the
         <a class="drug drug_general" data-topicid="104541" href="/z/d/drug information/104541.html" rel="external">
          LNG IUDs
         </a>
         may include reduction in heavy menstrual bleeding, dysmenorrhea, and endometrial hyperplasia, as well as suppression of menses [
         <a href="#rid43">
          43,50,51
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         IUDs can be described to adolescent patients as follows [
         <a href="#rid52">
          52
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         "IUDs are completely reversible contraceptive methods placed in the uterus. There are two types of IUDs. One is hormonal and lasts up to three or five years. The other is nonhormonal; it releases copper and can last up to 10 years. Either type can be removed at any time if you wish to become pregnant or want to switch to a new method. They are very safe and have the highest satisfaction and continuation rates of any contraception method."
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The pregnancy rate is &lt;1 percent per year in typical patients, and slightly higher in females younger than 25 years [
         <a href="#rid53">
          53,54
         </a>
         ]. Fertility returns quickly after removal.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         There are relatively few
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Freproductivehealth%2Fcontraception%2Fpdf%2Fsummary-chart-us-medical-eligibility-criteria_508tagged.pdf&amp;token=p7A56cdQa48oh8HfN4dMPEKlrim7QFIQY%2FuVV%2FJckGU937u1ckJkmkgaK8H2PBoY%2FJ5BEapx7DHdp5gqM%2BK1cZFvupA973jfwqlDuJ3YBVeBCZhIb4QeOsKswDD%2B1dvSISE9r%2BIvb9WDleMu0Qs%2FMQ%3D%3D&amp;TOPIC_ID=107" target="_blank">
          absolute (unacceptable health risks) or relative (theoretic or proven risks usually outweigh the advantages) contraindications
         </a>
         to intrauterine contraception [
         <a href="#rid55">
          55
         </a>
         ]. These include severe distortion of the uterine cavity, active pelvic infection, known or suspected pregnancy, Wilson disease (for the
         <a class="drug drug_general" data-topicid="93719" href="/z/d/drug information/93719.html" rel="external">
          copper IUD
         </a>
         ), unexplained vaginal bleeding (for initiation of intrauterine contraception), breast cancer (for the
         <a class="drug drug_general" data-topicid="104541" href="/z/d/drug information/104541.html" rel="external">
          LNG IUD
         </a>
         ), and hepatocellular adenoma or hepatoma (for the LNG IUD). (See
         <a class="medical medical_review" href="/z/d/html/5419.html" rel="external">
          "Intrauterine contraception: Candidates and device selection", section on 'Contraindications'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         With adequate counseling regarding anticipated side effects and management of anticipated side effects, IUDs can be used safely and effectively in adolescents [
         <a href="#rid43">
          43,56
         </a>
         ]. There is little difference in infection and complication rates between adolescents and older females [
         <a href="#rid44">
          44,57-59
         </a>
         ]. Although some studies have reported an increased expulsion rate in young or nulliparous adolescents, the findings are inconsistent. (See
         <a class="medical medical_review" href="/z/d/html/116579.html" rel="external">
          "Intrauterine contraception: Background and device types"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5419.html" rel="external">
          "Intrauterine contraception: Candidates and device selection"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5422.html" rel="external">
          "Intrauterine contraception: Management of side effects and complications"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Contraceptive implant
         </strong>
         – The etonogestrel contraceptive implant is an attractive option for adolescents who desire long-term, uninterrupted contraception [
         <a href="#rid43">
          43,49
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The contraceptive implant can be described to adolescent patients as follows [
         <a href="#rid52">
          52
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         "The contraceptive implant is a single flexible plastic rod placed under the skin of your upper arm. It is hormonal and lasts up to three years. It can be removed if you wish to become pregnant or would like to switch to a different method."
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The pregnancy rate is &lt;1 percent per year in typical patients [
         <a href="#rid54">
          54
         </a>
         ]. Fertility returns quickly after removal.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Freproductivehealth%2Fcontraception%2Fpdf%2Fsummary-chart-us-medical-eligibility-criteria_508tagged.pdf&amp;token=p7A56cdQa48oh8HfN4dMPEKlrim7QFIQY%2FuVV%2FJckGU937u1ckJkmkgaK8H2PBoY%2FJ5BEapx7DHdp5gqM%2BK1cZFvupA973jfwqlDuJ3YBVeBCZhIb4QeOsKswDD%2B1dvSISE9r%2BIvb9WDleMu0Qs%2FMQ%3D%3D&amp;TOPIC_ID=107" target="_blank">
          Absolute (unacceptable health risks) and relative (theoretic or proven risks usually outweigh the advantages) contraindications
         </a>
         to the contraceptive implant include known or suspected pregnancy, severe (decompensated) cirrhosis, hepatocellular adenoma or hepatoma, undiagnosed abnormal vaginal bleeding, systemic lupus erythematosus with positive or unknown antiphospholipid antibodies, and known or suspected breast cancer or history of breast cancer [
         <a href="#rid55">
          55
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3266.html" rel="external">
          "Contraception: Etonogestrel implant", section on 'Patient selection'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Unexpected and prolonged vaginal bleeding is a common side effect and can trigger request for premature removal. Easy access to clinic staff to provide management advice in such situations is critical. (See
         <a class="local">
          'Whom to contact with questions'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/3266.html" rel="external">
          "Contraception: Etonogestrel implant", section on 'Counseling points'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5474.html" rel="external">
          "Evaluation and management of unscheduled bleeding in individuals using hormonal contraception", section on 'Progestin-releasing implants'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1127198982">
         <span class="h3">
          Depot medroxyprogesterone acetate
         </span>
         <span class="headingEndMark">
          —
         </span>
         Depot
         <a class="drug drug_general" data-topicid="9600" href="/z/d/drug information/9600.html" rel="external">
          medroxyprogesterone acetate
         </a>
         (DMPA) is an injectable progestin-only contraceptive that provides effective, private, reversible contraception for three months. Noncontraceptive benefits of DMPA include protection against ovarian cancer, endometrial cancer, salpingitis, ectopic pregnancy, benign breast disease, acne, and iron deficiency.
        </p>
        <p>
         The pregnancy rate is 4 to 7 percent per year in typical patients [
         <a href="#rid60">
          60,61
         </a>
         ]. Return to fertility may be delayed for more than a year. (See
         <a class="medical medical_review" href="/z/d/html/5468.html" rel="external">
          "Depot medroxyprogesterone acetate (DMPA): Formulations, patient selection and drug administration", section on 'Return to fertility after discontinuation'
         </a>
         .)
        </p>
        <p>
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Freproductivehealth%2Fcontraception%2Fpdf%2Fsummary-chart-us-medical-eligibility-criteria_508tagged.pdf&amp;token=p7A56cdQa48oh8HfN4dMPEKlrim7QFIQY%2FuVV%2FJckGU937u1ckJkmkgaK8H2PBoY%2FJ5BEapx7DHdp5gqM%2BK1cZFvupA973jfwqlDuJ3YBVeBCZhIb4QeOsKswDD%2B1dvSISE9r%2BIvb9WDleMu0Qs%2FMQ%3D%3D&amp;TOPIC_ID=107" target="_blank">
          Absolute (unacceptable health risks) and relative contraindications (theoretic or proven risks usually outweigh the advantages) contraindications
         </a>
         to
         <a class="drug drug_general" data-topicid="9600" href="/z/d/drug information/9600.html" rel="external">
          DMPA
         </a>
         , most of which are unlikely in adolescents, include [
         <a href="#rid55">
          55
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Multiple risk factors for cardiovascular disease (eg, older age, smoking, diabetes, hypertension, low high-density-lipoprotein [HDL] cholesterol, high low-density-lipoprotein [LDL] cholesterol, high triglycerides)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Vascular disease in patients with hypertension
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ischemic heart disease or stroke
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Systemic lupus erythematosus with severe thrombocytopenia (relative contraindication to initiation of
         <a class="drug drug_general" data-topicid="9600" href="/z/d/drug information/9600.html" rel="external">
          DMPA
         </a>
         , but not continuation) or positive (or unknown) antiphospholipid antibodies
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Rheumatoid arthritis and receiving long-term corticosteroid therapy with a history of or risk factors for nontraumatic fractures
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Unexplained abnormal vaginal bleeding
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Breast cancer
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Diabetes with nephropathy, retinopathy, neuropathy, or other vascular disease or diabetes of &gt;20 years' duration
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Severe (decompensated) cirrhosis, hepatocellular adenoma, hepatoma
        </p>
        <p>
        </p>
        <p>
         (See
         <a class="medical medical_review" href="/z/d/html/5468.html" rel="external">
          "Depot medroxyprogesterone acetate (DMPA): Formulations, patient selection and drug administration", section on 'Patient selection'
         </a>
         .)
        </p>
        <p>
         Menstrual changes (eg, unscheduled bleeding, amenorrhea) are a common side effect of
         <a class="drug drug_general" data-topicid="9600" href="/z/d/drug information/9600.html" rel="external">
          DMPA
         </a>
         and a frequent reason for discontinuation. (See
         <a class="medical medical_review" href="/z/d/html/118540.html" rel="external">
          "Depot medroxyprogesterone acetate (DMPA): Efficacy, side effects, metabolic impact, and benefits", section on 'Side effects'
         </a>
         .)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9600" href="/z/d/drug information/9600.html" rel="external">
          DMPA
         </a>
         is associated with decreased bone mineral density, which appears to be reversible [
         <a href="#rid62">
          62
         </a>
         ], and it is important to discuss this possibility with the adolescent patient. However, the potential risk(s) of DMPA must be weighed against the potential benefit of pregnancy prevention [
         <a href="#rid27">
          27
         </a>
         ]. Despite the boxed warning that DMPA should not be used for longer than two years unless other methods are inadequate [
         <a href="#rid63">
          63
         </a>
         ], professional organizations suggest that with adequate explanation of potential risks and benefits, DMPA may be prescribed to adolescent girls who need contraception and may be used for more than two years [
         <a href="#rid42">
          42,64
         </a>
         ]. In a multicenter observational study of adolescents with bone density loss during DMPA use, 14 of 15 subjects had vitamin D deficiency/insufficiency [
         <a href="#rid65">
          65
         </a>
         ]. Thus, to mitigate the risk of decreased bone density, adolescents who choose DMPA are encouraged to take 1300 mg of elemental calcium and 600 to 1000 international units of
         <a class="drug drug_general" data-topicid="10117" href="/z/d/drug information/10117.html" rel="external">
          vitamin D3
         </a>
         (calciferol) or D2 (
         <a class="drug drug_general" data-topicid="10150" href="/z/d/drug information/10150.html" rel="external">
          ergocalciferol
         </a>
         ) per day and to exercise every day [
         <a href="#rid42">
          42,64,65
         </a>
         ]. Decisions regarding monitoring of bone mineral density and estrogen supplementation should be made on a case-by-case basis. (See
         <a class="medical medical_review" href="/z/d/html/5355.html" rel="external">
          "Bone health and calcium requirements in adolescents"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/118540.html" rel="external">
          "Depot medroxyprogesterone acetate (DMPA): Efficacy, side effects, metabolic impact, and benefits", section on 'Reduction in bone mineral density'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1458454894">
         <span class="h3">
          Pill, patch, or ring
         </span>
         <span class="headingEndMark">
          —
         </span>
         Combined oral contraceptive pills, the contraceptive patch, and the vaginal ring are hormonal methods of contraception that contain both estrogen and progestin.
        </p>
        <p>
         The pregnancy rate with these methods is 4 to 7 percent per year in typical patients [
         <a href="#rid60">
          60,61
         </a>
         ]. Noncontraceptive benefits of combined hormonal contraception include improved bone density and protection against ovarian cancer, endometrial cancer, salpingitis, ectopic pregnancy, benign breast disease, acne, and iron deficiency. (See
         <a class="medical medical_review" href="/z/d/html/7398.html" rel="external">
          "Combined estrogen-progestin oral contraceptives: Patient selection, counseling, and use", section on 'Counseling points'
         </a>
         .)
        </p>
        <p>
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Freproductivehealth%2Fcontraception%2Fpdf%2Fsummary-chart-us-medical-eligibility-criteria_508tagged.pdf&amp;token=p7A56cdQa48oh8HfN4dMPEKlrim7QFIQY%2FuVV%2FJckGU937u1ckJkmkgaK8H2PBoY%2FJ5BEapx7DHdp5gqM%2BK1cZFvupA973jfwqlDuJ3YBVeBCZhIb4QeOsKswDD%2B1dvSISE9r%2BIvb9WDleMu0Qs%2FMQ%3D%3D&amp;TOPIC_ID=107" target="_blank">
          Absolute (unacceptable health risks) and relative contraindications (theoretic or proven risks usually outweigh the advantages) contraindications
         </a>
         to estrogen-progestin contraceptives include [
         <a href="#rid55">
          55
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Multiple
         </strong>
         risk factors for arterial cardiovascular disease (eg, older age, smoking, diabetes, hypertension, low HDL cholesterol, high LDL cholesterol, high triglycerides)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Vascular disease
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hypertension
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ischemic heart disease or stroke
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Known thrombophilia and thrombogenic mutations including antiphospholipid syndrome and factor V Leiden; prothrombin mutation; protein S, protein C, and antithrombin deficiencies
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Deep vein thrombosis (DVT) and pulmonary embolism (PE) (past history of DVT/PE and not taking anticoagulant therapy or DVT/PE and taking anticoagulant therapy for ≥3 months)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Superficial venous thrombosis (acute or history)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Increased risk of thromboembolism (includes &lt;21 days postpartum, whether breastfeeding or not)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Complicated valvular heart disease
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Migraine with aura
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Breast cancer
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Diabetes with nephropathy, retinopathy, neuropathy, or other vascular disease or diabetes of &gt;20 years' duration
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Medically treated gallbladder disease
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Acute viral hepatitis or flare of viral hepatitis (contraindication to initiation, but not continuation of combined hormonal contraception)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Severe (decompensated) cirrhosis, hepatocellular adenoma, hepatoma
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         History of surgery for obesity with a malabsorption procedure (eg, biliopancreatic diversion, jejunoileal bypass, Roux-en-Y bypass); this is a relative contraindication only for combined oral contraceptive pills, not for the contraceptive patch or the vaginal ring (see
         <a class="medical medical_review" href="/z/d/html/5470.html" rel="external">
          "Contraception: Counseling for females with obesity", section on 'Contraception pre- and post-bariatric surgery'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Major surgery or multiple sclerosis with prolonged immobilization
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Drug interactions such as certain antiretroviral therapies, anticonvulsant medications,
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H550588765">
         <span class="h4">
          Combined oral contraceptives
         </span>
         <span class="headingEndMark">
          —
         </span>
         Combined oral contraceptive pills require the adolescent to take a pill daily and to remember to refill their prescription. Combination oral contraceptive pills usually are taken for 21 consecutive days followed by 7 days of no pill or placebo pills, during which menstrual bleeding occurs. (See
         <a class="medical medical_review" href="/z/d/html/7398.html" rel="external">
          "Combined estrogen-progestin oral contraceptives: Patient selection, counseling, and use", section on 'Cyclic use'
         </a>
         .)
        </p>
        <p>
         Adolescents who wish to avoid monthly periods for medical or lifestyle reasons may choose to follow a schedule that involves continuous estrogen-progestin pills for 84 days followed by a week of pill-free days. In addition, a combination oral contraceptive that provides continuous, year-round contraception is available. Adolescents who choose to follow a continuous pill or extended cycle regimen should be advised that unscheduled bleeding may occur during the initial cycles but generally decreases with prolonged use. Continuous pill and extended cycle regimens are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5423.html" rel="external">
          "Hormonal contraception for menstrual suppression"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7398.html" rel="external">
          "Combined estrogen-progestin oral contraceptives: Patient selection, counseling, and use", section on 'Continuous or extended use'
         </a>
         .)
        </p>
        <p>
         In addition to the general contraindications for estrogen-progestin contraception described above, certain medications or herbal therapies may decrease the effectiveness of oral contraceptives. These include ritonavir-boosted protease inhibitors for the treatment of human immunodeficiency virus (HIV) infection, anticonvulsants,
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         and
         <a class="drug drug_general" data-topicid="8502" href="/z/d/drug information/8502.html" rel="external">
          griseofulvin
         </a>
         (though not most other antimicrobials), and St. John's Wort. (See
         <a class="medical medical_review" href="/z/d/html/7398.html" rel="external">
          "Combined estrogen-progestin oral contraceptives: Patient selection, counseling, and use", section on 'Drug interactions'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3753.html" rel="external">
          "HIV and women", section on 'Choice of contraception'
         </a>
         .)
        </p>
        <p>
         Specific interactions of combined oral contraceptive pills with other medications may be determined with the
         <a class="external" href="/drug-interactions">
          Lexicomp drug interactions
         </a>
         tool included with UpToDate.
        </p>
        <p class="headingAnchor" id="H867795359">
         <span class="h4">
          Transdermal patch
         </span>
         <span class="headingEndMark">
          —
         </span>
         The transdermal is applied weekly (at a different site) for three weeks, followed by a patch-free week.
        </p>
        <p>
         Nonhormonal side-effects of the contraceptive patch include application site reactions. Mild itching with irritation and redness can be managed by removing and discarding the patch and placing a new patch in another location. Severe itching with more severe redness and swelling may indicate an allergic reaction, in which case the patch should be removed and discarded and an alternative contraceptive method sought. (See
         <a class="medical medical_review" href="/z/d/html/5425.html" rel="external">
          "Contraception: Transdermal contraceptive patches", section on 'Side effects'
         </a>
         .)
        </p>
        <p>
         In addition to the general contraindications for estrogen-progestin contraception described above, obesity (body mass index &gt;30 kg/m
         <sup>
          2
         </sup>
         or ≥95
         <sup>
          th
         </sup>
         percentile for age (
         <a class="calc calc_professional" href="/z/d/html/13415.html" rel="external">
          calculator 1
         </a>
         )) is a contraindication for transdermal contraceptive patches [
         <a href="#rid66">
          66,67
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5425.html" rel="external">
          "Contraception: Transdermal contraceptive patches", section on 'Contraindications'
         </a>
         .)
        </p>
        <p>
         Additional information about patch management, including what to do if the patch becomes detached, is provided separately. (See
         <a class="medical medical_review" href="/z/d/html/5425.html" rel="external">
          "Contraception: Transdermal contraceptive patches", section on 'Patch management'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H95914185">
         <span class="h4">
          Vaginal ring
         </span>
         <span class="headingEndMark">
          —
         </span>
         The vaginal ring  (
         <a class="graphic graphic_figure graphicRef115021" href="/z/d/graphic/115021.html" rel="external">
          figure 2
         </a>
         ) is inserted into the vagina by the patient. It is left in place for three weeks and then removed for a single ring-free week. The vaginal ring is available in one size – it does not need to be fitted. (See
         <a class="medical medical_review" href="/z/d/html/16682.html" rel="external">
          "Contraception: Hormonal contraceptive vaginal rings"
         </a>
         .)
        </p>
        <p>
         Fertility returns within one month after discontinuation.
        </p>
        <p>
         Adolescents who choose the vaginal ring must be comfortable inserting it into the vagina. Adolescents who use tampons during menses may be more comfortable with this procedure.
        </p>
        <p>
         Anecdotal evidence suggests that some adolescents do not feel "clean" with the vaginal ring and remove it frequently for washing. Frequent washing decreases effectiveness and may cause intermittent bleeding or spotting.
        </p>
        <p class="headingAnchor" id="H593908528">
         <span class="h3">
          Other methods
         </span>
         <span class="headingEndMark">
          —
         </span>
         Barrier (condoms, diaphragms, cervical caps, sponges) and other methods of contraception (eg, spermicides, periodic abstinence [ie, the "calendar rhythm" method], withdrawal) are less effective because they require action on the part of the adolescent and/or partner at the time of sexual activity.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          External condoms
         </strong>
         – The effectiveness of external condoms (commonly called "condoms" [formerly "male condoms"]) for pregnancy prevention depends upon whether they are used consistently and correctly. With consistent, correct use, the pregnancy rate is 2 percent; with typical use it is 13 percent [
         <a href="#rid60">
          60,61
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5463.html" rel="external">
          "External (formerly male) condoms"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The effectiveness of external condoms for STI prevention is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7595.html" rel="external">
          "Prevention of sexually transmitted infections", section on 'Male condom use'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other methods
         </strong>
         – Other methods of contraception are infrequently used by adolescents [
         <a href="#rid6">
          6
         </a>
         ]. They are discussed separately:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Diaphragm, cervical cap, and sponge (see
         <a class="medical medical_review" href="/z/d/html/3265.html" rel="external">
          "Pericoital (on demand) contraception: Diaphragm, cervical cap, spermicides, and sponge"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Internal (formerly female) condom (see
         <a class="medical medical_review" href="/z/d/html/5471.html" rel="external">
          "Internal (formerly female) condoms"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Fertility awareness-based methods (see
         <a class="medical medical_review" href="/z/d/html/5456.html" rel="external">
          "Fertility awareness-based methods of pregnancy prevention"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H799882607">
         <span class="h2">
          Special circumstances
         </span>
        </p>
        <p class="headingAnchor" id="H3204737341">
         <span class="h3">
          Physical or intellectual disability
         </span>
         <span class="headingEndMark">
          —
         </span>
         Adolescents with physical disability may have difficulty with menstrual hygiene. For such adolescents, hormonal contraception (eg,
         <a class="drug drug_general" data-topicid="104541" href="/z/d/drug information/104541.html" rel="external">
          LNG IUD
         </a>
         ,
         <a class="drug drug_general" data-topicid="9600" href="/z/d/drug information/9600.html" rel="external">
          DMPA
         </a>
         , the contraceptive patch, or continuous or extended cycles of combined oral contraceptive pills) may be beneficial [
         <a href="#rid43">
          43,68-73
         </a>
         ]. The intellectually disabled adolescent has access to contraception under the supervision of a parent or guardian. (See
         <a class="local">
          'Choosing a method'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/5423.html" rel="external">
          "Hormonal contraception for menstrual suppression"
         </a>
         .)
        </p>
        <p>
         Issues regarding sterilization among females with mental illness or disability are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/101560.html" rel="external">
          "Overview of female permanent contraception", section on 'Vulnerable populations'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1225565610">
         <span class="h3">
          Obesity
         </span>
         <span class="headingEndMark">
          —
         </span>
         Contraception for obese females is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5470.html" rel="external">
          "Contraception: Counseling for females with obesity"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3238571464">
         <span class="h3">
          Postpartum or postabortion
         </span>
         <span class="headingEndMark">
          —
         </span>
         Contraception for adolescents who are postpartum or postabortion is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6708.html" rel="external">
          "Contraception: Postpartum counseling and methods"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1943732895">
         <span class="h3">
          Chronic illness
         </span>
         <span class="headingEndMark">
          —
         </span>
         For adolescents with chronic illness, it is important to consider the possibility of hormone-related complications and drug interactions, as well as the risk a pregnancy might pose to the adolescent's health. For some adolescents, progestin-only contraception (eg,
         <a class="drug drug_general" data-topicid="9600" href="/z/d/drug information/9600.html" rel="external">
          DMPA
         </a>
         ,
         <a class="drug drug_general" data-topicid="8870" href="/z/d/drug information/8870.html" rel="external">
          etonogestrel implant
         </a>
         ,
         <a class="drug drug_general" data-topicid="104541" href="/z/d/drug information/104541.html" rel="external">
          LNG IUD
         </a>
         ) may be reasonable; for others, nonhormonal options are available; among these, the
         <a class="drug drug_general" data-topicid="93719" href="/z/d/drug information/93719.html" rel="external">
          copper IUD
         </a>
         is the most effective  (
         <a class="graphic graphic_table graphicRef89046" href="/z/d/graphic/89046.html" rel="external">
          table 2
         </a>
         ). The risks of the various contraceptive options must be weighed against the risk of pregnancy [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
         Specific recommendations for contraceptive methods in patients with medical or psychiatric issues are provided separately:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Inherited thrombophilias (see
         <a class="medical medical_review" href="/z/d/html/5479.html" rel="external">
          "Contraception: Counseling for women with inherited thrombophilias"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Systemic lupus erythematosus (see
         <a class="medical medical_review" href="/z/d/html/95507.html" rel="external">
          "Approach to contraception in women with systemic lupus erythematosus"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         HIV infection (see
         <a class="medical medical_review" href="/z/d/html/3753.html" rel="external">
          "HIV and women", section on 'Choice of contraception'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Bipolar disorder (see
         <a class="medical medical_review" href="/z/d/html/15701.html" rel="external">
          "Bipolar disorder in women: Contraception and preconception assessment and counseling"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Other conditions (see
         <a class="medical medical_review" href="/z/d/html/5459.html" rel="external">
          "Contraception: Counseling and selection", section on 'Special populations'
         </a>
         )
        </p>
        <p>
        </p>
        <p>
         Specific interactions of combined oral contraceptive pills with other medications may be determined with the
         <a class="external" href="/drug-interactions">
          Lexicomp drug interactions
         </a>
         tool included with UpToDate.
        </p>
        <p class="headingAnchor" id="H2021889695">
         <span class="h2">
          Options for emergency contraception
         </span>
         <span class="headingEndMark">
          —
         </span>
         EC refers to methods that prevent pregnancy from occurring after an episode of unprotected intercourse. Unprotected intercourse can be a result of contraception nonuse or imperfect use, or can result from forced sexual activity. EC does not interrupt an existing pregnancy; thus, it does
         <strong>
          not
         </strong>
         cause abortion. EC options for adolescents are the same as for adults. (See
         <a class="medical medical_review" href="/z/d/html/5475.html" rel="external">
          "Emergency contraception", section on 'What are the emergency contraception methods?'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3317427789">
         <span class="h1">
          PREINITIATION COUNSELING
         </span>
        </p>
        <p class="headingAnchor" id="H2773118788">
         <span class="h2">
          Whom to contact with questions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Adolescents who are initiating contraception should be given an easy-to-read list that includes:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The name of the clinic
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The name or title (eg, charge nurse) of the appropriate contact person in the clinic
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The clinic phone number
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Instructions about what to do if they have any concerns about their contraceptive method
        </p>
        <p>
        </p>
        <p>
         Easy access to clinic staff for counseling helps to ensure consistent and correct use of contraception. Adolescents should not rely on their friends or family for information if they have a problem with their contraceptive method.
        </p>
        <p class="headingAnchor" id="H3105370507">
         <span class="h2">
          STI prevention
         </span>
         <span class="headingEndMark">
          —
         </span>
         Adolescents who choose effective methods of contraception (eg, long-acting reversible contraception, depot
         <a class="drug drug_general" data-topicid="9600" href="/z/d/drug information/9600.html" rel="external">
          medroxyprogesterone acetate
         </a>
         , combined hormonal contraception) must understand that these methods do not prevent sexually transmitted infections (STI) [
         <a href="#rid74">
          74
         </a>
         ]. To prevent STI as well as pregnancy, consistent and correct use of a condom is necessary [
         <a href="#rid42">
          42,75
         </a>
         ]. Consistent and correct use of male latex condoms reduces the risk STI, including HIV. (See
         <a class="medical medical_review" href="/z/d/html/7595.html" rel="external">
          "Prevention of sexually transmitted infections", section on 'Male condom use'
         </a>
         .)
        </p>
        <p>
         Other strategies to prevent STI include vaccines (eg, human papillomavirus, hepatitis B, hepatitis A) and antimicrobial prophylaxis. These strategies are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7595.html" rel="external">
          "Prevention of sexually transmitted infections"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3455884924">
         <span class="h2">
          Availability of emergency contraception
         </span>
         <span class="headingEndMark">
          —
         </span>
         Adolescents who choose methods of contraception other than an intrauterine device or a contraceptive implant should be educated about the availability of and indications for emergency contraception in the event of a gap in contraceptive use or a method failure [
         <a href="#rid41">
          41,76
         </a>
         ]. This is particularly true for adolescents who require medical treatments that may be teratogenic to the fetus (eg,
         <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">
          isotretinoin
         </a>
         ) or in whom pregnancy would severely compromise health (eg, severe mitral stenosis, symptomatic aortic stenosis, Eisenmenger syndrome) [
         <a href="#rid77">
          77,78
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1422.html" rel="external">
          "Pregnancy in women with congenital heart disease: General principles", section on 'Maternal risk stratification'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/139887.html" rel="external">
          "Pulmonary hypertension with congenital heart disease: Pregnancy and contraception"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2716538850">
         <span class="h2">
          Issues related to removal or discontinuation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Before initiation, we counsel adolescents about issues related to removal of long-acting reversible methods of contraception methods or discontinuation of hormonal contraceptive methods. We prioritize visits (by phone, video, or in-person) for adolescents who request removal of intrauterine devices and contraceptive implants to prevent self-removal. We counsel adolescents who are considering other methods about the risk of pregnancy, bleeding, and missed menstrual periods after discontinuation. These issues are discussed in detail separately:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Intrauterine devices (see
         <a class="medical medical_review" href="/z/d/html/3267.html" rel="external">
          "Intrauterine contraception: Insertion and removal", section on 'IUD removal (with or without replacement)'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Contraceptive implants (see
         <a class="medical medical_review" href="/z/d/html/3266.html" rel="external">
          "Contraception: Etonogestrel implant", section on 'Removal and return of ovulation'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Depot
         <a class="drug drug_general" data-topicid="9600" href="/z/d/drug information/9600.html" rel="external">
          medroxyprogesterone acetate
         </a>
         (see
         <a class="medical medical_review" href="/z/d/html/5468.html" rel="external">
          "Depot medroxyprogesterone acetate (DMPA): Formulations, patient selection and drug administration", section on 'Discontinuation'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Combined estrogen-progestin oral contraceptives (see
         <a class="medical medical_review" href="/z/d/html/7398.html" rel="external">
          "Combined estrogen-progestin oral contraceptives: Patient selection, counseling, and use", section on 'Return of menses after stopping'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Contraceptive patch (see
         <a class="medical medical_review" href="/z/d/html/5425.html" rel="external">
          "Contraception: Transdermal contraceptive patches", section on 'Return of fertility'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Contraceptive vaginal ring (see
         <a class="medical medical_review" href="/z/d/html/16682.html" rel="external">
          "Contraception: Hormonal contraceptive vaginal rings", section on 'Return of fertility'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3489964897">
         <span class="h1">
          INITIATION AND INCREASING ADHERENCE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most methods of contraception can be initiated without a pelvic examination [
         <a href="#rid34">
          34,79
         </a>
         ]. Strategies to increase contraceptive adherence vary with the method of contraception  (
         <a class="graphic graphic_table graphicRef52699" href="/z/d/graphic/52699.html" rel="external">
          table 3
         </a>
         ). Increasing correct and consistent use of contraception is critical; contraceptive misuse (rather than lack of use) accounts for nearly one-half of unintended pregnancies [
         <a href="#rid80">
          80
         </a>
         ].
        </p>
        <p>
         Although it is generally not necessary to obtain written informed consent before initiation of contraception in adolescents (with the exception of the contraceptive implant), the use of a structured informed consent form can ensure that the risks, benefits, and anticipated side effects are adequately discussed. Benefits and risks, effectiveness, potential side effects including the boxed warnings for depot
         <a class="drug drug_general" data-topicid="9600" href="/z/d/drug information/9600.html" rel="external">
          medroxyprogesterone acetate
         </a>
         (DMPA), complications and danger signs of complications, and indications for discontinuation of the chosen contraceptive method must be included on the consent form. The consent forms must be written in a language understood by the adolescent or translated and witnessed by an interpreter.
        </p>
        <p class="headingAnchor" id="H2385906738">
         <span class="h2">
          LARC
         </span>
         <span class="headingEndMark">
          —
         </span>
         Long-acting reversible methods of contraception (LARC) do not require strategies to increase adherence; their efficacy does not require any action on the part of the adolescent.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Intrauterine contraception
         </strong>
         – Screening for sexually transmitted infections (STI) and a bimanual pelvic examination with cervical inspection are performed before insertion of an intrauterine device (IUD). Unless the adolescent is at very high risk for STI (eg, had sex with a partner with known gonorrhea), STI screening may take place at the time of IUD insertion [
         <a href="#rid42">
          42
         </a>
         ]. If detected, STI can be treated with the IUD in place [
         <a href="#rid34">
          34,81
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         It is helpful for clinicians who are not trained to insert IUDs in nulliparous and parous teens to establish a relationship with a clinic or provider(s) who perform this procedure. We refer patients who require insertion under sedation (eg, some patients with cerebral palsy) to a trained provider, such as a pediatric or adolescent gynecologist or adolescent medicine specialist.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The insertion of intrauterine contraceptive devices and management of side effects are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/3267.html" rel="external">
          "Intrauterine contraception: Insertion and removal"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5422.html" rel="external">
          "Intrauterine contraception: Management of side effects and complications"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Contraceptive implants
         </strong>
         – Written informed consent is necessary before insertion of the contraceptive implant – the consent form is included in the box containing the implant. Pregnancy should be excluded before insertion of the etonogestrel contraceptive implant [
         <a href="#rid34">
          34
         </a>
         ]. The implant is ideally inserted on the same day as the request, using the Quick Start method  (
         <a class="graphic graphic_algorithm graphicRef56863" href="/z/d/graphic/56863.html" rel="external">
          algorithm 1
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/3266.html" rel="external">
          "Contraception: Etonogestrel implant"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         However, some practitioners are hesitant to insert the implant if they are not absolutely certain that pregnancy has been excluded or when emergency contraception cannot be taken (eg, the adolescent cannot recall the date of the last episode of protected or unprotected sexual activity). In this situation, the provider may prescribe a single injection of
         <a class="drug drug_general" data-topicid="9600" href="/z/d/drug information/9600.html" rel="external">
          DMPA
         </a>
         using the Quick Start method  (
         <a class="graphic graphic_algorithm graphicRef56863" href="/z/d/graphic/56863.html" rel="external">
          algorithm 1
         </a>
         ). This approach provides immediate contraception and in the event the pregnancy test becomes positive, the implant does not need to be removed prematurely. Providing anticipatory guidance to caregivers and adolescents about this approach can minimize misunderstanding and expectations for Quick Start implant insertion in sexually active adolescents. (See
         <a class="local">
          'DMPA'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The insertion of the etonogestrel contraceptive implant and postinsertion counseling are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/3266.html" rel="external">
          "Contraception: Etonogestrel implant"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5474.html" rel="external">
          "Evaluation and management of unscheduled bleeding in individuals using hormonal contraception", section on 'Progestin-releasing implants'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H513887077">
         <span class="h2">
          DMPA
         </span>
         <span class="headingEndMark">
          —
         </span>
         The first shot of
         <a class="drug drug_general" data-topicid="9600" href="/z/d/drug information/9600.html" rel="external">
          DMPA
         </a>
         is typically given during the menstrual period to ensure absence of pregnancy. Alternatively, DMPA can be administered according to the Quick Start method  (
         <a class="graphic graphic_algorithm graphicRef56863" href="/z/d/graphic/56863.html" rel="external">
          algorithm 1
         </a>
         ) [
         <a href="#rid82">
          82
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5468.html" rel="external">
          "Depot medroxyprogesterone acetate (DMPA): Formulations, patient selection and drug administration", section on 'Timing of injections'
         </a>
         .)
        </p>
        <p>
         Adolescents who choose
         <a class="drug drug_general" data-topicid="9600" href="/z/d/drug information/9600.html" rel="external">
          DMPA
         </a>
         may need support for continued use. Strategies to increase continuation of DMPA include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Scheduling the appointment for the next injection immediately after each shot
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Allowing for missed or delayed appointments by scheduling injections 11 to 12 weeks apart rather than 13 to 15 weeks [
         <a href="#rid83">
          83,84
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Instructing the adolescent to set a mobile phone reminder
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Using an automated text messaging reminder system [
         <a href="#rid85">
          85,86
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Self-administration of subcutaneous
         <a class="drug drug_general" data-topicid="9600" href="/z/d/drug information/9600.html" rel="external">
          DMPA
         </a>
         may be an option for select adolescents [
         <a href="#rid87">
          87
         </a>
         ] (see
         <a class="medical medical_review" href="/z/d/html/5468.html" rel="external">
          "Depot medroxyprogesterone acetate (DMPA): Formulations, patient selection and drug administration", section on 'Injection techniques'
         </a>
         )
        </p>
        <p>
        </p>
        <p>
         In a prospective study of urban adolescents who were provided contraception at no cost, the 12-month continuation rate for
         <a class="drug drug_general" data-topicid="9600" href="/z/d/drug information/9600.html" rel="external">
          DMPA
         </a>
         among adolescents 14 to 19 years was only 47 percent [
         <a href="#rid48">
          48
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H261808072">
         <span class="h2">
          Pill, patch, or ring
         </span>
         <span class="headingEndMark">
          —
         </span>
         Combined hormonal contraceptive methods include estrogen-progestin oral contraceptives, the contraceptive patch, and the vaginal ring.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Estrogen-progestin oral contraceptives
         </strong>
         – Oral contraceptives can be started at any time. To ensure that the first pill is taken, a "same day" or Quick Start method is the preferred approach  (
         <a class="graphic graphic_algorithm graphicRef56863" href="/z/d/graphic/56863.html" rel="external">
          algorithm 1
         </a>
         ) [
         <a href="#rid88">
          88
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7398.html" rel="external">
          "Combined estrogen-progestin oral contraceptives: Patient selection, counseling, and use", section on 'Initiation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         As an alternative to the Quick Start method, oral contraceptives can be started on the first day of the next menstrual period or the Sunday after the onset of the menstrual period ("Sunday start method"). Starting oral contraceptives during or soon after the next menstrual period helps make sure that the adolescent is not pregnant. However, when initiation of oral contraceptives is delayed, adolescents may never take the first pill. Failure to begin the pill may occur due to ambivalence, confusion about starting instructions, or intervening pregnancy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Adolescents who choose oral contraceptive pills need support for continued and correct use, which entails:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Refilling prescriptions
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Taking the pill every day
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Starting the subsequent pack on time
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Using a "back-up" method of contraception when necessary
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Providing clear verbal and written instructions and reviewing the instructions with the actual pill pack (if possible) or a sample pack may increase continuation and adherence. If the adolescent does not have sufficient reading skills to interpret labels and instructions, instructions may be recorded on the adolescent's mobile phone or they may be referred to instructions at a reliable website (eg, "Birth Control Basics" available on the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fyoungwomenshealth.org%2Fguides%2Fbirth-control-pills%2F&amp;token=WyjrFyLMmu2orQkJCuuCqEREYx4y7kfuqH9QoG0YQyoNmlP94f%2Bluwi1W8nVFj2oC07T4fiAren5AdBUlxnFaA%3D%3D&amp;TOPIC_ID=107" target="_blank">
          Center for Young Women's Health website
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         To optimize adherence with oral contraceptives, we suggest giving an adolescent only three things to remember:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         When to start the pill
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Take the pill every day at the same time, especially when doing something else regularly, like teeth brushing
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Call the clinic/office if there are any questions (see
         <a class="local">
          'Whom to contact with questions'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The adolescent should be asked to repeat these three instructions to assess and promote their understanding of them.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Additional strategies to increase continuation may include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Using an automated text messaging system to provide a daily reminder to take the pill [
         <a href="#rid86">
          86,89,90
         </a>
         ]
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Prescribing or providing up to one year of oral contraceptive pills at a time (if insurance permits) [
         <a href="#rid44">
          44
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a prospective study of urban adolescents who were provided contraception at no cost, the 12-month continuation rate for oral contraceptives among adolescents 14 to 19 years was only 47 percent [
         <a href="#rid48">
          48
         </a>
         ]. In other observational studies, missing pills was common in both adolescent and adult females [
         <a href="#rid91">
          91,92
         </a>
         ]. In a study limited to adolescents aged 14 to 17 years, the average interval of consecutive pill use was only 32.5 days [
         <a href="#rid91">
          91
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Transdermal patch
         </strong>
         – The transdermal patch can be initiated according to the Quick Start method  (
         <a class="graphic graphic_algorithm graphicRef56863" href="/z/d/graphic/56863.html" rel="external">
          algorithm 1
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/5425.html" rel="external">
          "Contraception: Transdermal contraceptive patches", section on 'Initiation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Strategies to increase adherence to weekly changes include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Making a note or setting a reminder on a wall, computer, or cell phone calendar
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Using a weekly cell phone alarm
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Placing a sticker designating the change day on the bathroom mirror
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a prospective study of urban adolescents who were provided contraception at no cost, only 21 adolescents age 14 to 19 years chose the transdermal patch; of these, the 12-month continuation rate was only 41 percent [
         <a href="#rid48">
          48
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Vaginal ring
         </strong>
         – The vaginal ring can be initiated according to the Quick Start method  (
         <a class="graphic graphic_algorithm graphicRef56863" href="/z/d/graphic/56863.html" rel="external">
          algorithm 1
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/16682.html" rel="external">
          "Contraception: Hormonal contraceptive vaginal rings"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Strategies to increase adherence to the schedule of insertion for three weeks followed by a ring-free week include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Making a note or setting a reminder on a wall, computer, or cell phone calendar
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Using a cell phone alarm
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Placing a sticker designating the removal/reinsertion days on the bathroom mirror
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4032899466">
         <span class="h2">
          Barrier methods
         </span>
         <span class="headingEndMark">
          —
         </span>
         Strategies to increase the use of external (formerly male) condoms in sexually active adolescents include [
         <a href="#rid32">
          32,93
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Provision of external condoms before the patient leaves the office or clinic
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Provision of practical suggestions to ensure availability (eg, keeping condoms in a purse)
        </p>
        <p>
        </p>
        <p>
         Additional strategies to promote effective condom use are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5463.html" rel="external">
          "External (formerly male) condoms", section on 'Strategies for promoting effective external condom use'
         </a>
         .)
        </p>
        <p>
         Barrier methods other than external condoms are infrequently used by adolescents [
         <a href="#rid6">
          6
         </a>
         ]. They are discussed separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Diaphragm, cervical cap and sponge (see
         <a class="medical medical_review" href="/z/d/html/3265.html" rel="external">
          "Pericoital (on demand) contraception: Diaphragm, cervical cap, spermicides, and sponge"
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Internal (formerly female) condom (see
         <a class="medical medical_review" href="/z/d/html/5471.html" rel="external">
          "Internal (formerly female) condoms"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4031668426">
         <span class="h1">
          FOLLOW-UP
         </span>
         <span class="headingEndMark">
          —
         </span>
         Sexually active adolescent and young adult females should be seen whenever they have symptoms of sexually transmitted infection (STI) or require review of potential side effects of their contraceptive method  (
         <a class="graphic graphic_table graphicRef89046" href="/z/d/graphic/89046.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid34">
          34
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/115.html" rel="external">
          "Sexually transmitted infections: Issues specific to adolescents"
         </a>
         .)
        </p>
        <p>
         Some methods of contraception require specific follow-up as indicated below:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Depot
         </strong>
         <a class="drug drug_general" data-topicid="9600" href="/z/d/drug information/9600.html" rel="external">
          medroxyprogesterone acetate
         </a>
         – Every 13 weeks for repeat injection. When injection is necessary before 13 weeks, documentation of the rationale (eg, lack of transportation) may help with third party reimbursement. The Centers for Disease Control and Prevention practice recommendations indicate that early injection can be given when necessary with no time limit (eg, when the adolescent cannot return at the routine interval) [
         <a href="#rid84">
          84
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Combined oral contraceptive pills/vaginal ring/patch
         </strong>
         – The refill intervals for combined hormonal contraception may vary depending upon the payment method. If possible, a 12-month supply of pills, rings, or patches should be provided annually. However, some payment providers may require shorter refill intervals.
        </p>
        <p>
        </p>
        <p>
         In addition to acute visits for symptoms of STI, side effects of contraception, or contraceptive refills, adolescents and young adult females should have an annual visit for health maintenance and preventive care. The components of this visit are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/108.html" rel="external">
          "Guidelines for adolescent preventive services"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2872.html" rel="external">
          "Screening tests in children and adolescents"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/115.html" rel="external">
          "Sexually transmitted infections: Issues specific to adolescents", section on 'STI clinical patterns'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H534777903">
         <span class="h1">
          RESOURCES FOR CLINICIANS AND PATIENTS
         </span>
        </p>
        <p>
         For clinicians:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.acog.org%2Fprograms%2Flong-acting-reversible-contraception-larc&amp;token=U83nmWJdEnYplmY9VjWreX3HVdeM4iV5pW6eK0VWJFBp3n3w1ajFQOAV2mS7Cgk1PHjvV%2B4Qkzpl360fr4RK8M6MULij1Bk7TNBpJyQfoTk%3D&amp;TOPIC_ID=107" target="_blank">
          ACOG LARC program
         </a>
         – American College of Obstetricians and Gynecologists Long-Acting Reversible Contraception Program.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.choiceproject.wustl.edu%2F&amp;token=%2BnVJmPhZ7CoZ6P5TTscsQMEfRjhRSH%2BHYjLFHmNv8MpZBNOY80TFEfWmQJ4v5GVF&amp;TOPIC_ID=107" target="_blank">
          CHOICE Project
         </a>
         – A free website sponsored by the Washington University School of Medicine that provides resources on contraceptive options and training for clinicians.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Freproductivehealth%2Fcontraception%2Fmmwr%2Fmec%2Fsummary.html&amp;token=gn9CxBU9SK4%2Bjug8DleFYAmCahKbgv18S9Zgv5fBNxTGoMdTGRC8XnfLV%2BmDF%2FKgq%2FUbcwPNhHygS%2BUPWWe15o2kSqIPMCtrmL2KJwaUlwQ%3D&amp;TOPIC_ID=107" target="_blank">
          United States Medical Eligibility Criteria for Contraceptive Use (2016).
         </a>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Freproductivehealth%2Fcontraception%2Fmmwr%2Fspr%2Fsummary.html&amp;token=Zv1nEgBzkE2cJgq1MJWYyowGAMyfjs4EoZNt3JvsEOYBr9FvR7BP3rQriZh8ccgOyWP1sWbw7etjgCZDsbk4G1a%2BIaBrwia1URQaVtzLGZs%3D&amp;TOPIC_ID=107" target="_blank">
          United States Selected Practice Recommendations for Contraceptive Use (2016)
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.who.int%2Fpublications%2Fi%2Fitem%2F9789241549158&amp;token=mr3MkQMxxRm373pPGLTYB%2B8L7rJeOJtqYOfpSLq18h7bLDDnWC3XicBcpsIGU3t1%2BeMBqFM7dNdQ9NPFnY3uWg%3D%3D&amp;TOPIC_ID=107" target="_blank">
          World Health Organization Medical Eligibility Criteria for Contraceptive Use
         </a>
         and
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.who.int%2Fpublications%2Fi%2Fitem%2F9789241549257&amp;token=mr3MkQMxxRm373pPGLTYB%2B8L7rJeOJtqYOfpSLq18h7bLDDnWC3XicBcpsIGU3t1KmE%2BlIH4Up7JMM8N%2B0%2B%2BQw%3D%3D&amp;TOPIC_ID=107" target="_blank">
          2015 Medical Eligibility Criteria Wheel for Contraceptive Use
         </a>
         .
        </p>
        <p>
        </p>
        <p>
         For patients:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.acog.org%2Fwomens-health%2Ffaqs%2Fbirth-control&amp;token=jSCn%2Fb0RICb%2FRmzHKJAs3gl8FvTNjpB9PblH3onCkVT0lcUoVurCC0ViYnGXCfuM0f%2Bgj4IalxcwaoaQdtveEg%3D%3D&amp;TOPIC_ID=107" target="_blank">
          ACOG Frequently Asked Questions Especially for Teens
         </a>
         – American College of Obstetricians and Gynecologists frequently asked questions about contraception.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.acog.org%2Fwomens-health%2Fexperts-and-stories%2Fthe-latest%2Fwhat-i-wish-all-teens-knew-about-long-acting-birth-control&amp;token=DQtGS28qULFSb7PGhVuM3PUFQGeHS2opBuq8dvXmXHoHe6TlcK5bFpZLW6NMOB2%2FvYif%2FAo1g%2BQJIBKYdDw%2FotrHRQMBEJKx69nU0peQB4Oe3s%2FXNrVBRPUqdSe6DHnOhQcCtHHhu0bnQD22KCt8bg%3D%3D&amp;TOPIC_ID=107" target="_blank">
          ACOG Expert View on long-acting birth control
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.bedsider.org%2F&amp;token=h7Ird6MEQJ0ciS3wlIS74wS%2BbqJQEspyaSo36FRNdkGJJnrJaPDlUEGuXmILPu5F&amp;TOPIC_ID=107" target="_blank">
          bedsider.org
         </a>
         – A free website developed by the private, nonprofit National Campaign to Prevent Teen and Unplanned Pregnancy; includes descriptions and a comparison of the various method and offers to set up automated email or text reminders for appointments, pills, injections, etc.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fyoungwomenshealth.org%2F&amp;token=9SOQ31M5muHbxxUii9uduj7uOdQP%2BNVKJGoE4M4lyiOJKXEoosD%2FJno5DMXZnUfG&amp;TOPIC_ID=107" target="_blank">
          Center for Young Women's Health
         </a>
         – A free website run by Boston Children's Hospital that addresses reproductive health needs of teens and young adults.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.plannedparenthood.org%2F&amp;token=xXI%2By9QNEPjV52%2B%2BDeHAeZ9SXc2ukqt22nAmmnoIhbmjKCcbIKeiWKTXDj94bQ%2F4&amp;TOPIC_ID=107" target="_blank">
          Planned Parenthood
         </a>
         – A not-for-profit organization dedicated to reproductive health with resources for patients and clinicians.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.sexandu.ca%2F&amp;token=vdCs7dqmABYrTYLl86e3UBvZDVaCgDBYOgHXgKrHwtk%3D&amp;TOPIC_ID=107" target="_blank">
          SexualityandU.ca
         </a>
         – An educational site run by the Society of Obstetricians and Gynaecologists of Canada that includes descriptions of various methods and a tool to help with selection of birth control.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1421293648">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/112268.html" rel="external">
          "Society guideline links: Contraception"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/117836.html" rel="external">
          "Society guideline links: Adolescent sexual health and pregnancy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H34">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or email these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient education" and the keyword[s] of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/15914.html" rel="external">
          "Patient education: Teen sexuality (The Basics)"
         </a>
         and
         <a class="medical medical_basics" href="/z/d/html/15349.html" rel="external">
          "Patient education: Choosing birth control (The Basics)"
         </a>
         and
         <a class="medical medical_basics" href="/z/d/html/16162.html" rel="external">
          "Patient education: Hormonal birth control (The Basics)"
         </a>
         and
         <a class="medical medical_basics" href="/z/d/html/86385.html" rel="external">
          "Patient education: Long-acting methods of birth control (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (see
         <a class="medical medical_patient" href="/z/d/html/1206.html" rel="external">
          "Patient education: Adolescent sexuality (Beyond the Basics)"
         </a>
         and
         <a class="medical medical_patient" href="/z/d/html/8419.html" rel="external">
          "Patient education: Hormonal methods of birth control (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H35">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Motivating factors
         </strong>
         – Sexually active adolescents are more likely to seek contraception if they perceive pregnancy as a negative outcome, have long-term educational goals, are more mature, experience a pregnancy scare or actual pregnancy, or have family, friends, and/or a clinician who sanction the use of contraception. (See
         <a class="local">
          'Motivating factors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Potential barriers
         </strong>
         – Potential barriers to adolescent contraception include access to affordable contraception; concerns about confidentiality and parental notification; cost; misperceptions about the risk of unintended pregnancy; and misperceptions about the effectiveness of, contraindications to, preinitiation evaluation for, and adverse effects of various methods of contraception. (See
         <a class="local">
          'Potential barriers'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patient factors and preferences
         </strong>
         – A medical, reproductive/sexual, and social history will identify
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Freproductivehealth%2Fcontraception%2Fpdf%2Fsummary-chart-us-medical-eligibility-criteria_508tagged.pdf&amp;token=p7A56cdQa48oh8HfN4dMPEKlrim7QFIQY%2FuVV%2FJckGU937u1ckJkmkgaK8H2PBoY%2FJ5BEapx7DHdp5gqM%2BK1cZFvupA973jfwqlDuJ3YBVeBCZhIb4QeOsKswDD%2B1dvSISE9r%2BIvb9WDleMu0Qs%2FMQ%3D%3D&amp;TOPIC_ID=107" target="_blank">
          absolute (unacceptable health risks) or relative (theoretic or proven risks usually outweigh the advantages) contraindications
         </a>
         , patient factors (eg, acne, dysmenorrhea), and individual patient preferences (eg, ease of use) that may affect contraceptive choice  (
         <a class="graphic graphic_table graphicRef89046" href="/z/d/graphic/89046.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="local">
          'Patient factors and preferences'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Presenting options
         </strong>
         – When presenting options for contraception to adolescents, we describe them in order of effectiveness, starting with the most effective methods (ie, intrauterine contraception and the contraceptive implant)  (
         <a class="graphic graphic_figure graphicRef119765" href="/z/d/graphic/119765.html" rel="external">
          figure 1
         </a>
         ). We discuss effectiveness, contraindications, anticipated side effects (eg, unscheduled vaginal bleeding), adverse effects, and noncontraceptive benefits). (See
         <a class="local">
          'Presenting options'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Preinitiation counseling
         </strong>
         – Before initiating contraception, we provide general information about whom to contact with questions, the need to use condoms to prevent sexually transmitted infections (STI), and the availability and indications for emergency contraception. (See
         <a class="local">
          'Preinitiation counseling'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Initiation and increasing adherence
         </strong>
         – At the time of initiation of contraception, written informed consent can be obtained but is not required unless the chosen method is a contraceptive implant or intrauterine device or the contraception is provided in a federal or state-funded family planning clinic. A discussion about strategies to increase adherence  (
         <a class="graphic graphic_table graphicRef52699" href="/z/d/graphic/52699.html" rel="external">
          table 3
         </a>
         ) is also helpful. (See
         <a class="local">
          'Initiation and increasing adherence'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Follow-up
         </strong>
         – Sexually active adolescent and young adult females should be seen whenever they have symptoms of STI, require review of potential side effects, or request removal of their contraceptive method  (
         <a class="graphic graphic_table graphicRef89046" href="/z/d/graphic/89046.html" rel="external">
          table 2
         </a>
         ). The frequency of contraception-related follow-up varies with the method (eg, repeat injection every 13 weeks for depot
         <a class="drug drug_general" data-topicid="9600" href="/z/d/drug information/9600.html" rel="external">
          medroxyprogesterone acetate
         </a>
         ; annual or more frequent refills for contraceptive pills, patch, or vaginal ring). In addition to acute visits for symptoms of STI, side effects of contraception, or contraceptive refills/repeat injections, adolescents and young adult females should have an annual visit for health maintenance and preventive care. (See
         <a class="local">
          'Follow-up'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Finer LB, Zolna MR. Declines in Unintended Pregnancy in the United States, 2008-2011. N Engl J Med 2016; 374:843.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Szucs LE, Lowry R, Fasula AM, et al. Condom and Contraceptive Use Among Sexually Active High School Students - Youth Risk Behavior Survey, United States, 2019. MMWR Suppl 2020; 69:11.
          </a>
         </li>
         <li class="breakAll">
          Centers for Disease Control and Prevention. High School YRBS. Youth Online. https://nccd.cdc.gov/Youthonline/App/Default.aspx (Accessed on May 23, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Szucs LE, Pampati S, Li J, et al. Role of the COVID-19 Pandemic on Sexual Behaviors and Receipt of Sexual and Reproductive Health Services Among U.S. High School Students - Youth Risk Behavior Survey, United States, 2019-2021. MMWR Suppl 2023; 72:55.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abma JC, Martinez GM. Sexual Activity and Contraceptive Use Among Teenagers in the United States, 2011-2015. Natl Health Stat Report 2017; :1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martinez GM, Abma JC. Sexual Activity, Contraceptive Use, and Childbearing of Teenagers Aged 15-19 in the United States. NCHS Data Brief 2015; :1.
          </a>
         </li>
         <li class="breakAll">
          Nelson AI, Neinstein LS. Contraception. In: Handbook of Adolescent Health Care, Neinstein LS, Gordon CM, Katzman DK, et al (Eds), Lippincott Williams &amp; Wilkins, 2009. p.389.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kavanaugh ML, Frohwirth L, Jerman J, et al. Long-acting reversible contraception for adolescents and young adults: patient and provider perspectives. J Pediatr Adolesc Gynecol 2013; 26:86.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kavanaugh ML, Jerman J, Ethier K, Moskosky S. Meeting the contraceptive needs of teens and young adults: youth-friendly and long-acting reversible contraceptive services in U.S. family planning facilities. J Adolesc Health 2013; 52:284.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pritt NM, Norris AH, Berlan ED. Barriers and Facilitators to Adolescents' Use of Long-Acting Reversible Contraceptives. J Pediatr Adolesc Gynecol 2017; 30:18.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Secura GM, Madden T, McNicholas C, et al. Provision of no-cost, long-acting contraception and teenage pregnancy. N Engl J Med 2014; 371:1316.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harper CC, Rocca CH, Thompson KM, et al. Reductions in pregnancy rates in the USA with long-acting reversible contraception: A cluster randomised trial. Lancet 2015; 386:562.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Secura GM, Adams T, Buckel CM, et al. Change in sexual behavior with provision of no-cost contraception. Obstet Gynecol 2014; 123:771.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thompson KM, Rocca CH, Kohn JE, et al. Public Funding for Contraception, Provider Training, and Use of Highly Effective Contraceptives: A Cluster Randomized Trial. Am J Public Health 2016; 106:541.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oringanje C, Meremikwu MM, Eko H, et al. Interventions for preventing unintended pregnancies among adolescents. Cochrane Database Syst Rev 2016; 2:CD005215.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Winner B, Peipert JF, Zhao Q, et al. Effectiveness of long-acting reversible contraception. N Engl J Med 2012; 366:1998.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carlson J, Goldstein R, Hoover K, Tyson N. NASPAG/SAHM Statement: The 21st Century Cures Act and Adolescent Confidentiality. J Adolesc Health 2021; 68:426.
          </a>
         </li>
         <li class="breakAll">
          The Patient Protection and Affordable Care Act. Public Law No. 111-148 (2010). http://www.dol.gov/ebsa/healthreform/ (Accessed on March 22, 2016).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chuang CH, Mitchell JL, Velott DL, et al. Women's Awareness of Their Contraceptive Benefits Under the Patient Protection and Affordable Care Act. Am J Public Health 2015; 105 Suppl 5:S713.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Society for Adolescent Health and Medicine, American Academy of Pediatrics. Confidentiality Protections for Adolescents and Young Adults in the Health Care Billing and Insurance Claims Process. J Adolesc Health 2016; 58:374.
          </a>
         </li>
         <li class="breakAll">
          Guttmacher Institute. State laws and policies. Insurance Coverage of Contraceptives. https://www.guttmacher.org/state-policy/explore/insurance-coverage-contraceptives (Accessed on May 31, 2016).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chacko MR, Wiemann CM, Buzi RS, et al. Choice of Postpartum Contraception: Factors Predisposing Pregnant Adolescents to Choose Less Effective Methods Over Long-Acting Reversible Contraception. J Adolesc Health 2016; 58:628.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Truehart A, Whitaker A. Contraception for the adolescent patient. Obstet Gynecol Surv 2015; 70:263.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Committee Opinion No. 710: Counseling Adolescents About Contraception. Obstet Gynecol 2017; 130:e74. Reaffirmed 2022.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coates C, Gordon CM, Simpson T. A Qualitative Study Exploring Contraceptive Practices and Barriers to Long-Acting Reversible Contraceptive Use in a Sample of Adolescents Living in the Southern United States. J Pediatr Adolesc Gynecol 2018; 31:605.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Espey E, Yoder K, Hofler L. Barriers and Solutions to Improve Adolescent Intrauterine Device Access. J Pediatr Adolesc Gynecol 2019; 32:S7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gordon CM, Pitts SA. Approach to the adolescent requesting contraception. J Clin Endocrinol Metab 2012; 97:9.
          </a>
         </li>
         <li class="breakAll">
          WHO Medical Eligibility Criteria Wheel for contraceptive use, 2015. World Health Organization. Available at: https://srhr.org/mecwheel/.
         </li>
         <li class="breakAll">
          Contraceptive and reproductive services for teens: Evidence-based clinical best practices. Centers for Disease Control and Prevention. Available at: https://www.cdc.gov/teenpregnancy/pdf/about/Fact-Sheet-Contraceptive-Reproductive-Health-Services-Teens_TAGGED-508.pdf (Accessed on April 11, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mollen C, Ketterer T, Min J, et al. Expanding Contraceptive Access for Teens-Leveraging the Pediatric Emergency Department. J Adolesc Health 2023; 73:155.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoopes AJ, Timko CA, Akers AY. What's Known and What's Next: Contraceptive Counseling and Support for Adolescents and Young Adult Women. J Pediatr Adolesc Gynecol 2021; 34:484.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Richards MJ, Buyers E. Update on Adolescent Contraception. Adv Pediatr 2016; 63:429.
          </a>
         </li>
         <li class="breakAll">
          Barrel RL, Gold MA. Contraception. In: Neinstein’s Adolescent and Young Adult Health Care: A Practical Guide, 6th ed, Neinstein LS, Katzman DK, Callahan ST, et al (Eds), Wolters Kluwer, 2016. p.353.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Curtis KM, Jatlaoui TC, Tepper NK, et al. U.S. Selected Practice Recommendations for Contraceptive Use, 2016. MMWR Recomm Rep 2016; 65:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clarke KE, Kraft JM, Wiener JB, et al. Factors Associated with Contraceptive Use Differ between Younger and Older African-American Female Adolescents. J Pediatr Adolesc Gynecol 2016; 29:448.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kumar MM. Long-Acting Reversible Contraceptives for Adolescents: More Complex Than "First-Line". JAMA Pediatr 2018; 172:6.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Melo J, Peters M, Teal S, Guiahi M. Adolescent and Young Women's Contraceptive Decision-Making Processes: Choosing "The Best Method for Her". J Pediatr Adolesc Gynecol 2015; 28:224.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nguyen LN, Jamieson MA. Adolescent users of an online contraception selection tool: how user preferences and characteristics differ from those of adults. J Pediatr Adolesc Gynecol 2011; 24:317.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rubin SE, Felsher M, Korich F, Jacobs AM. Urban Adolescents' and Young Adults' Decision-Making Process around Selection of Intrauterine Contraception. J Pediatr Adolesc Gynecol 2016; 29:234.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brückner H, Bearman P. After the promise: the STD consequences of adolescent virginity pledges. J Adolesc Health 2005; 36:271.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Upadhya KK, COMMITTEE ON ADOLESCENCE. Emergency Contraception. Pediatrics 2019; 144.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Committee on Adolescence. Contraception for adolescents. Pediatrics 2014; 134:e1244.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Menon S, COMMITTEE ON ADOLESCENCE. Long-Acting Reversible Contraception: Specific Issues for Adolescents. Pediatrics 2020; 146.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Committee on Adolescent Health Care Long-Acting Reversible Contraception Working Group, The American College of Obstetricians and Gynecologists. Committee opinion no. 539: Adolescents and long-acting reversible contraception: Implants and intrauterine devices. Obstet Gynecol 2012; 120:983.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Committee on Gynecologic Practice Long-Acting Reversible Contraception Working Group. Committee Opinion No. 642: Increasing Access to Contraceptive Implants and Intrauterine Devices to Reduce Unintended Pregnancy. Obstet Gynecol 2015; 126:e44. Reaffirmed 2018.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Committee on Practice Bulletins-Gynecology, Long-Acting Reversible Contraception Work Group. Practice Bulletin No. 186: Long-Acting Reversible Contraception: Implants and Intrauterine Devices. Obstet Gynecol 2017; 130:e251. Reaffirmed 2019.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Usinger KM, Gola SB, Weis M, Smaldone A. Intrauterine Contraception Continuation in Adolescents and Young Women: A Systematic Review. J Pediatr Adolesc Gynecol 2016; 29:659.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosenstock JR, Peipert JF, Madden T, et al. Continuation of reversible contraception in teenagers and young women. Obstet Gynecol 2012; 120:1298.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McNicholas C, Swor E, Wan L, Peipert JF. Prolonged use of the etonogestrel implant and levonorgestrel intrauterine device: 2 years beyond Food and Drug Administration-approved duration. Am J Obstet Gynecol 2017.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adeyemi-Fowode OA, Bercaw-Pratt JL. Intrauterine Devices: Effective Contraception with Noncontraceptive Benefits for Adolescents. J Pediatr Adolesc Gynecol 2019; 32:S2.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bayer LL, Hillard PJ. Use of levonorgestrel intrauterine system for medical indications in adolescents. J Adolesc Health 2013; 52:S54.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Secura GM, Allsworth JE, Madden T, et al. The Contraceptive CHOICE Project: reducing barriers to long-acting reversible contraception. Am J Obstet Gynecol 2010; 203:115.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heinemann K, Reed S, Moehner S, Minh TD. Comparative contraceptive effectiveness of levonorgestrel-releasing and copper intrauterine devices: The European active surveillance study for intrauterine devices. Contraception 2015; 91:280.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Teal S, Edelman A. Contraception Selection, Effectiveness, and Adverse Effects: A Review. JAMA 2021; 326:2507.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Curtis KM, Tepper NK, Jatlaoui TC, et al. U.S. Medical Eligibility Criteria for Contraceptive Use, 2016. MMWR Recomm Rep 2016; 65:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hillard PJA. Practical Tips for Intrauterine Device Counseling, Insertion, and Pain Relief in Adolescents: An Update. J Pediatr Adolesc Gynecol 2019; 32:S14.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Deans EI, Grimes DA. Intrauterine devices for adolescents: a systematic review. Contraception 2009; 79:418.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Díaz J, Pinto Neto AM, Bahamondes L, et al. Performance of the copper T 200 in parous adolescents: are copper IUDs suitable for these women? Contraception 1993; 48:23.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Birgisson NE, Zhao Q, Secura GM, et al. Positive testing for Neisseria gonorrhoeae and Chlamydia trachomatis and the risk of pelvic inflammatory disease in IUD users. J Womens Health (Larchmt) 2015; 24:354.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sundaram A, Vaughan B, Kost K, et al. Contraceptive Failure in the United States: Estimates from the 2006-2010 National Survey of Family Growth. Perspect Sex Reprod Health 2017; 49:7.
          </a>
         </li>
         <li class="breakAll">
          Contraceptive Technology. Table 26-1: Percentage of women experiencing an unintended pregnancy during the first year of typical use and the first year of perfect use of contraception and the percentage continuing use at the end of the first year: United States. 2018. http://www.contraceptivetechnology.org/wp-content/uploads/2013/09/Contraceptive-Failure-Rates.pdf (Accessed on March 15, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scholes D, LaCroix AZ, Ichikawa LE, et al. Change in bone mineral density among adolescent women using and discontinuing depot medroxyprogesterone acetate contraception. Arch Pediatr Adolesc Med 2005; 159:139.
          </a>
         </li>
         <li class="breakAll">
          Black box warning added concerning long-term use of Depo-provera contraceptive injection. FDA Talk Paper. November 17, 2004. Available at: www.fda.gov/bbs/topics/ANSWERS/2004/ANS01325.html (Accessed on December 05, 2007).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cromer BA, Scholes D, Berenson A, et al. Depot medroxyprogesterone acetate and bone mineral density in adolescents--the Black Box Warning: a Position Paper of the Society for Adolescent Medicine. J Adolesc Health 2006; 39:296.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harel Z, Wolter K, Gold MA, et al. Inadequate vitamin D status in adolescents with substantial bone mineral density loss during the use of depot medroxyprogesterone acetate injectable contraceptive: a pilot study. J Pediatr Adolesc Gynecol 2010; 23:209.
          </a>
         </li>
         <li class="breakAll">
          Xulane- norelgestromin and ethinyl estradiol patch. US Food and Drug Administration (FDA) approved product information. Revised April, 2020. US National Library of Medicine. (Available online at www.dailymed.nlm.nih.gov (Accessed on July 7, 2020)).
         </li>
         <li class="breakAll">
          TWIRLA (levonorgestrel and ethinyl estradiol) transdermal system. US Food and Drug Administration (FDA) approved product information. Revised February, 2020. US National Library of Medicine. (Available online at www.dailymed.nlm.nih.gov (Accessed on July 7, 2020)).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ott MA, Sucato GS, Committee on Adolescence. Contraception for adolescents. Pediatrics 2014; 134:e1257.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           American College of Obstetricians and Gynecologists Committee on Adolescent Health Care. ACOG Committee Opinion No. 448: Menstrual manipulation for adolescents with disabilities. Obstet Gynecol 2009; 114:1428.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Quint EH, O'Brien RF, COMMITTEE ON ADOLESCENCE, North American Society for Pediatric and Adolescent Gynecology. Menstrual Management for Adolescents With Disabilities. Pediatrics 2016; 138.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leeks R, Bartley C, O'Brien B, et al. Menstrual Suppression in Pediatric and Adolescent Patients with Disabilities Ranging from Developmental to Acquired Conditions: A Population Study in an Australian Quaternary Pediatric and Adolescent Gynecology Service from January 2005 to December 2015. J Pediatr Adolesc Gynecol 2019; 32:535.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pradhan S, Gomez-Lobo V. Hormonal Contraceptives, Intrauterine Devices, Gonadotropin-releasing Hormone Analogues and Testosterone: Menstrual Suppression in Special Adolescent Populations. J Pediatr Adolesc Gynecol 2019; 32:S23.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwartz BI, Alexander M, Breech LL. Intrauterine Device Use in Adolescents With Disabilities. Pediatrics 2020; 146.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Steiner RJ, Liddon N, Swartzendruber AL, et al. Long-Acting Reversible Contraception and Condom Use Among Female US High School Students: Implications for Sexually Transmitted Infection Prevention. JAMA Pediatr 2016; 170:428.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Committee on Adolescent Health Care. Committee Opinion No 699: Adolescent Pregnancy, Contraception, and Sexual Activity. Obstet Gynecol 2017; 129:e142. Reaffirmed 2020.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Potter J, Santelli JS. Adolescent contraception: review and guidance for pediatric clinicians. Minerva Pediatr 2015; 67:33.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gold MA, Sucato GS, Conard LA, et al. Provision of emergency contraception to adolescents. J Adolesc Health 2004; 35:67.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stancil SL, Miller M, Briggs H, et al. Contraceptive Provision to Adolescent Females Prescribed Teratogenic Medications. Pediatrics 2016; 137.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Braverman PK, Breech L, Committee on Adolescence. American Academy of Pediatrics. Clinical report--gynecologic examination for adolescents in the pediatric office setting. Pediatrics 2010; 126:583.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Potter J, Soren K. Long-Acting Reversible Contraception and Condom Use: We Need a Better Message. JAMA Pediatr 2016; 170:417.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grimes DA. Intrauterine device and upper-genital-tract infection. Lancet 2000; 356:1013.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rickert VI, Tiezzi L, Lipshutz J, et al. Depo Now: preventing unintended pregnancies among adolescents and young adults. J Adolesc Health 2007; 40:22.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaunitz AM, Darney PD, Ross D, et al. Subcutaneous DMPA vs. intramuscular DMPA: a 2-year randomized study of contraceptive efficacy and bone mineral density. Contraception 2009; 80:7.
          </a>
         </li>
         <li class="breakAll">
          Centers for Disease Control and Prevention. U.S. Selected Practice Recommendations for Contraceptive Use, 2016 (US SPR). In: CDC Contraceptive Guidance for Health Care Providers. Available at: https://www.cdc.gov/reproductivehealth/contraception/contraception_guidance.htm#usspr.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trent M, Thompson C, Tomaszewski K. Text Messaging Support for Urban Adolescents and Young Adults Using Injectable Contraception: Outcomes of the DepoText Pilot Trial. J Adolesc Health 2015; 57:100.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith C, Gold J, Ngo TD, et al. Mobile phone-based interventions for improving contraception use. Cochrane Database Syst Rev 2015; :CD011159.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Curtis KM, Nguyen A, Reeves JA, et al. Update to U.S. Selected Practice Recommendations for Contraceptive Use: Self-Administration of Subcutaneous Depot Medroxyprogesterone Acetate. MMWR Morb Mortal Wkly Rep 2021; 70:739.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Westhoff C, Heartwell S, Edwards S, et al. Initiation of oral contraceptives using a quick start compared with a conventional start: a randomized controlled trial. Obstet Gynecol 2007; 109:1270.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Castaño PM, Bynum JY, Andrés R, et al. Effect of daily text messages on oral contraceptive continuation: a randomized controlled trial. Obstet Gynecol 2012; 119:14.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hou MY, Hurwitz S, Kavanagh E, et al. Using daily text-message reminders to improve adherence with oral contraceptives: a randomized controlled trial. Obstet Gynecol 2010; 116:633.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Woods JL, Shew ML, Tu W, et al. Patterns of oral contraceptive pill-taking and condom use among adolescent contraceptive pill users. J Adolesc Health 2006; 39:381.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moreau C, Bouyer J, Gilbert F, et al. Social, demographic and situational characteristics associated with inconsistent use of oral contraceptives: evidence from France. Perspect Sex Reprod Health 2006; 38:190.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grubb LK, COMMITTEE ON ADOLESCENCE. Barrier Protection Use by Adolescents During Sexual Activity. Pediatrics 2020; 146.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 107 Version 70.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26962904" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Declines in Unintended Pregnancy in the United States, 2008-2011.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32817600" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Condom and Contraceptive Use Among Sexually Active High School Students - Youth Risk Behavior Survey, United States, 2019.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32817600" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Condom and Contraceptive Use Among Sexually Active High School Students - Youth Risk Behavior Survey, United States, 2019.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37104536" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Role of the COVID-19 Pandemic on Sexual Behaviors and Receipt of Sexual and Reproductive Health Services Among U.S. High School Students - Youth Risk Behavior Survey, United States, 2019-2021.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28696201" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Sexual Activity and Contraceptive Use Among Teenagers in the United States, 2011-2015.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26199985" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Sexual Activity, Contraceptive Use, and Childbearing of Teenagers Aged 15-19 in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26199985" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Sexual Activity, Contraceptive Use, and Childbearing of Teenagers Aged 15-19 in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23287602" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Long-acting reversible contraception for adolescents and young adults: patient and provider perspectives.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23298980" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Meeting the contraceptive needs of teens and young adults: youth-friendly and long-acting reversible contraceptive services in U.S. family planning facilities.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27477904" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Barriers and Facilitators to Adolescents' Use of Long-Acting Reversible Contraceptives.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25271604" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Provision of no-cost, long-acting contraception and teenage pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26091743" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Reductions in pregnancy rates in the USA with long-acting reversible contraception: A cluster randomised trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24785603" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Change in sexual behavior with provision of no-cost contraception.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26794168" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Public Funding for Contraception, Provider Training, and Use of Highly Effective Contraceptives: A Cluster Randomized Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26839116" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Interventions for preventing unintended pregnancies among adolescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22621627" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Effectiveness of long-acting reversible contraception.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33541602" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : NASPAG/SAHM Statement: The 21st Century Cures Act and Adolescent Confidentiality.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33541602" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : NASPAG/SAHM Statement: The 21st Century Cures Act and Adolescent Confidentiality.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26447910" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Women's Awareness of Their Contraceptive Benefits Under the Patient Protection and Affordable Care Act.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26903437" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Confidentiality Protections for Adolescents and Young Adults in the Health Care Billing and Insurance Claims Process.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26903437" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Confidentiality Protections for Adolescents and Young Adults in the Health Care Billing and Insurance Claims Process.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26852250" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Choice of Postpartum Contraception: Factors Predisposing Pregnant Adolescents to Choose Less Effective Methods Over Long-Acting Reversible Contraception.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25900526" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Contraception for the adolescent patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28742675" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Committee Opinion No. 710: Counseling Adolescents About Contraception.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30012426" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : A Qualitative Study Exploring Contraceptive Practices and Barriers to Long-Acting Reversible Contraceptive Use in a Sample of Adolescents Living in the Southern United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31585618" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Barriers and Solutions to Improve Adolescent Intrauterine Device Access.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22223764" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Approach to the adolescent requesting contraception.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22223764" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Approach to the adolescent requesting contraception.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22223764" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Approach to the adolescent requesting contraception.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37330812" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Expanding Contraceptive Access for Teens-Leveraging the Pediatric Emergency Department.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33333260" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : What's Known and What's Next: Contraceptive Counseling and Support for Adolescents and Young Adult Women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27426910" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Update on Adolescent Contraception.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27426910" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Update on Adolescent Contraception.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27467319" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : U.S. Selected Practice Recommendations for Contraceptive Use, 2016.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26877099" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Factors Associated with Contraceptive Use Differ between Younger and Older African-American Female Adolescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29159411" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Long-Acting Reversible Contraceptives for Adolescents: More Complex Than "First-Line".
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26049939" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Adolescent and Young Women's Contraceptive Decision-Making Processes: Choosing "The Best Method for Her".
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21872777" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Adolescent users of an online contraception selection tool: how user preferences and characteristics differ from those of adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26363309" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Urban Adolescents' and Young Adults' Decision-Making Process around Selection of Intrauterine Contraception.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15780782" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : After the promise: the STD consequences of adolescent virginity pledges.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31740497" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Emergency Contraception.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25266430" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Contraception for adolescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32690806" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Long-Acting Reversible Contraception: Specific Issues for Adolescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22996129" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Committee opinion no. 539: Adolescents and long-acting reversible contraception: Implants and intrauterine devices.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26393458" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Committee Opinion No. 642: Increasing Access to Contraceptive Implants and Intrauterine Devices to Reduce Unintended Pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29064972" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Practice Bulletin No. 186: Long-Acting Reversible Contraception: Implants and Intrauterine Devices.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27386754" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Intrauterine Contraception Continuation in Adolescents and Young Women: A Systematic Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23168753" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Continuation of reversible contraception in teenagers and young women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28147241" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Prolonged use of the etonogestrel implant and levonorgestrel intrauterine device: 2 years beyond Food and Drug Administration-approved duration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31585615" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Intrauterine Devices: Effective Contraception with Noncontraceptive Benefits for Adolescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23535058" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Use of levonorgestrel intrauterine system for medical indications in adolescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20541171" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : The Contraceptive CHOICE Project: reducing barriers to long-acting reversible contraception.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25601350" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Comparative contraceptive effectiveness of levonorgestrel-releasing and copper intrauterine devices: The European active surveillance study for intrauterine devices.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34962522" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Contraception Selection, Effectiveness, and Adverse Effects: A Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27467196" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : U.S. Medical Eligibility Criteria for Contraceptive Use, 2016.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30802602" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Practical Tips for Intrauterine Device Counseling, Insertion, and Pain Relief in Adolescents: An Update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19442775" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Intrauterine devices for adolescents: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8403902" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Performance of the copper T 200 in parous adolescents: are copper IUDs suitable for these women?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25836384" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Positive testing for Neisseria gonorrhoeae and Chlamydia trachomatis and the risk of pelvic inflammatory disease in IUD users.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28245088" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Contraceptive Failure in the United States: Estimates from the 2006-2010 National Survey of Family Growth.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28245088" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Contraceptive Failure in the United States: Estimates from the 2006-2010 National Survey of Family Growth.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15699307" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Change in bone mineral density among adolescent women using and discontinuing depot medroxyprogesterone acetate contraception.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15699307" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Change in bone mineral density among adolescent women using and discontinuing depot medroxyprogesterone acetate contraception.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16857545" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Depot medroxyprogesterone acetate and bone mineral density in adolescents--the Black Box Warning: a Position Paper of the Society for Adolescent Medicine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20471875" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Inadequate vitamin D status in adolescents with substantial bone mineral density loss during the use of depot medroxyprogesterone acetate injectable contraceptive: a pilot study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20471875" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Inadequate vitamin D status in adolescents with substantial bone mineral density loss during the use of depot medroxyprogesterone acetate injectable contraceptive: a pilot study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20471875" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Inadequate vitamin D status in adolescents with substantial bone mineral density loss during the use of depot medroxyprogesterone acetate injectable contraceptive: a pilot study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25266435" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Contraception for adolescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20134299" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : ACOG Committee Opinion No. 448: Menstrual manipulation for adolescents with disabilities.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27325636" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Menstrual Management for Adolescents With Disabilities.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31181330" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Menstrual Suppression in Pediatric and Adolescent Patients with Disabilities Ranging from Developmental to Acquired Conditions: A Population Study in an Australian Quaternary Pediatric and Adolescent Gynecology Service from January 2005 to December 2015.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30980941" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Hormonal Contraceptives, Intrauterine Devices, Gonadotropin-releasing Hormone Analogues and Testosterone: Menstrual Suppression in Special Adolescent Populations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32719107" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Intrauterine Device Use in Adolescents With Disabilities.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26974492" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Long-Acting Reversible Contraception and Condom Use Among Female US High School Students: Implications for Sexually Transmitted Infection Prevention.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28426620" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Committee Opinion No 699: Adolescent Pregnancy, Contraception, and Sexual Activity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25358846" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Adolescent contraception: review and guidance for pediatric clinicians.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15230259" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Provision of emergency contraception to adolescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26676050" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Contraceptive Provision to Adolescent Females Prescribed Teratogenic Medications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20805151" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : American Academy of Pediatrics. Clinical report--gynecologic examination for adolescents in the pediatric office setting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26974055" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Long-Acting Reversible Contraception and Condom Use: We Need a Better Message.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11041414" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Intrauterine device and upper-genital-tract infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17185202" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Depo Now: preventing unintended pregnancies among adolescents and young adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19501210" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Subcutaneous DMPA vs. intramuscular DMPA: a 2-year randomized study of contraceptive efficacy and bone mineral density.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19501210" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Subcutaneous DMPA vs. intramuscular DMPA: a 2-year randomized study of contraceptive efficacy and bone mineral density.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26002432" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Text Messaging Support for Urban Adolescents and Young Adults Using Injectable Contraception: Outcomes of the DepoText Pilot Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26115146" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Mobile phone-based interventions for improving contraception use.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34014910" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Update to U.S. Selected Practice Recommendations for Contraceptive Use: Self-Administration of Subcutaneous Depot Medroxyprogesterone Acetate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17540797" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Initiation of oral contraceptives using a quick start compared with a conventional start: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22143257" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Effect of daily text messages on oral contraceptive continuation: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20733446" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Using daily text-message reminders to improve adherence with oral contraceptives: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16919800" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Patterns of oral contraceptive pill-taking and condom use among adolescent contraceptive pill users.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17162311" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Social, demographic and situational characteristics associated with inconsistent use of oral contraceptives: evidence from France.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32690808" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Barrier Protection Use by Adolescents During Sexual Activity.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
